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ABBREVIATIONS 
APS     Ammonium per sulfate 
ATP     Adenosine-5-triphosphate 
bFGF    Basic fibroblast growth factor 
BIM    Bisindolylmaleimide 
BSA     Bovine serum albumin 
CaCl2    Calcium chloride 
CPI-17   PKC-potentiated inhibitor 17-kDa protein 
DAG    Diacylglycerol 
DMSO    Dimethyl sulfoxide 
DTT     Dithiothreitol 
EC     Endothelial cell 
ECGS    Endothelial cell growth supplement 
ECL     Enhanced chemiluminescence 
EC-MLCK    Endothelial cell myosin light chain kinase 
EDTA    Ethylene diamine tetraacetic acid tetraacetic acid 
F-actin    Filamentous actin 
FCS     Fetal calf serum 
G-actin   Globular actin 
HBSS    Hanks' balanced salt solution 
hEGF    Human epidermal growth factor 
HEPES   4-(2-hydroxyethyl)-1-piperazine ethane sulfonic acid 
HUVEC   Human umbilical vein endothelial cells 
ICAM-1   Intercellular adhesion molecule-1 
KCl     Potassium chloride 
KH2PO4    Potassium dihydrogen phosphate 
kDa     Kilo dalton 
MgCl2    Magnesium chloride 
min     Minutes 
MLC     Myosin light chain 
MLC~P    Phosphorylated myosin light chain 
MLCK    Myosin light chain kinase 
MLCP    Myosin light chain phosphatase 
ML-7    1-(5-Iodonapthalene-1-sulfonyl)homopiperazine 
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MYPT1    Myosin phosphatase targeting subunit 1 
NaCl     Sodium chloride 
NaF     Sodium fluoride 
Na2HPO4    Di-sodium hydrogen phosphate 
NaH2PO4    Sodium dihydrogen phosphate 
Na-orthovanadate  Sodium orthovanadate 
Neg siRNA   Negative small interfering RNA 
NO    Nitric oxide 
NP-40    Nonidet P-40 
Pi    Phosphate 
PAEC    Porcine aortic endothelial cells 
PBS     Phosphate-buffered saline 
pH     Negative log of H+ concentration 
PKA     Protein kinase A 
PKC    Protein kinase C 
PMA    Phorbol-12-myristate-13-acetate 
PMSF    Phenylmethylsulfonyl fluoride 
PP1    Protein phosphatase 1 
ROCK   RhoA-associated protein kinase 
ROS    Reactive oxygen species 
SDS     Sodium dodecyl sulfate 
Ser19    Serine 19 
siRNA    Small interfering RNA 
Thr18    Threonine 18 
Thr38    Threonine 38 
Thr696    Threonine 696 
Thr850   Threonine 850 
TBS     Tris-buffered saline 
TEMED   N, N, N’, N’,-tetramethylethylenediamine 
Tris     Tris (hydroxymethyl) aminomethane 
U    Unit 
VE-cadherin    Vascular endothelial cadherin 
VEGF   Vascular endothelial growth factor 
% vol/vol    Volume by volume percentage 
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% wt/vol    Weight by volume percentage 
Y-27632   (1R,4r)-4-((R)-1aminoethyl)-N-(pyridine-4   
    yl)cyclohexanecarboxamide dihydrochloride 
ZO-1    Zona-occluden-1 
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1 INTRODUCTION 
 
1.1 Vascular Endothelium 
 
 The vascular endothelium originates from the mesoderm and lines the inner 
surfaces of all blood vessels and the cavities of the heart. Blood vessels are 
composed of three layers. The thick outer layer, the tunica adventitia, is made up of 
connective tissue. The middle layer, the tunica media, contains smooth muscle cells, 
which contract and dilate to maintain blood pressure. The interior lining, the tunica 
intima, is formed by a thin layer of endothelial cells (EC), denoted as endothelium. 
The endothelium fulfils a multitude of physiological functions. It is a selective “tissue-
blood barrier” between the vascular lumen and the interstitial space, maintains an 
antithrombotic and anticoagulant balance in the blood stream, and plays an important 
role in vasodilation/constriction. Endothelial dysfunction leads to the development of 
pathological processes such as leukocyte adherence, platelet activation, impaired 
coagulation pro-oxidation, mitogenesis, vascular inflammation, thrombosis, and 
atherosclerosis (Verma and Anderson, 2002). Therefore, the study of endothelial 
function during ischemia-reperfusion is an important tool to analyze the cause of 
cardiovascular diseases.  
 
1.2 Endothelium Permeability 
 
 The maintenance of a semi-permeable barrier by the endothelium is important 
for controlling the movement of ions, solutes, and macromolecules across the vessel 
wall. The elements regulating the integrity of the endothelium and endothelial 
permeability are: (1) cell-surface carrier proteins, (2) interendothelial junctions, (3) the 
electrostatic charge of endothelial membranes, and (4) the structure of the basal 
membrane. Among these, interendothelial junctions are one of the most important 
elements, which establish sites of physical attachment between two adjacent cell 
membranes. The transport of fluid and molecules across the endothelium occurs via 
transcellular and paracellular pathways. The transcellular pathway is involved in the 
transportation of macromolecular plasma proteins such as albumin by caveolae and 
vesiculo-vacuolar organelle (Feng et al., 1996), while small molecules such as 
glucose and plasma fluids pass the barrier through small gaps between EC on a 
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paracellular rout (Lewalle et al., 1997). Three types of interendothelial junctions have 
been found in EC: adherens junctions (Rubin, 1992), tight junctions (Gumbiner, 1993; 
Anderson et al., 1993), and gap junctions (Beyer, 1993).  
 
 Adherens junctions participate in the formation and stabilization of cell-cell 
adhesion and reorganization of the actin cytoskeleton. These junctions are formed by 
the members of transmembrane proteins family, cadherin that are linked to 
intracellular cytoskeletal and signaling molecules. The endothelial adherens junctions 
are formed from specific and non-specific types of cadherins: vascular endothelial 
(VE)-cadherin (Dejana et al., 1995), which is not found in other cells like blood cells 
or hematopoietic stem cells (Lampugnani et al., 1995) and neuronal (N)-cadherin, 
which is also present in other cell types, including neural cells and smooth muscle 
cells. The comparable significant amount of N-cadherin has been found in 
endothelium (Salomon et al., 1992). Other non-cell-type-specific cadherins, such as 
P-cadherin expression was detected by PCR analysis but could not be seen with 
antibody staining and T-cadherin was also expressed in different types of endothelial 
cells (Ivanov et al., 2001). 
 
 VE-cadherin makes a complexe through its cytoplasmic tail to the catenins (α, 
β, and γ-catenin or plakoglobin) (Lampugnani et al., 1995). β-catenin and plakoglobin 
are closely related and bind to α-catenin, which interacts with actin binding proteins, 
such as α-actinin and zonula occludens-1 (ZO-1) (Weis and Nelson, 2006). The 
binding of VE-cadherin with catenins is important to perform their adhesive function. 
The extracellular domain of VE-cadherin is necessary to make the first contact and 
clustering of the molecule while the association of cytoplasmic domain with actin 
cytoskeleton through catenins is important for the strength of the complex and control 
of vascular permeability (Navarro et al., 1995). Tyrosine phosphorylation of adherens 
junction proteins such as VE-cadherin and its linker catenin is associated with weak 
junctions and impaired vascular permeability. The vascular permeability increasing 
factors such as tumor necrosis factor-α (Angelini et al., 2006), histamine 
(Andriopoulou et al., 1999; Shasby et al., 2002), platelet-activating factor (Hudry-
Clergeon et al., 2005), and VEGF (Esser et al., 1998) provoke the tyrosine 
phosphorylation of VE-cadherin and catenins. The tyrosine phosphorylation of VE-
cadherin is also induced by the adhesion of leukocytes to endothelial cells via 
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intercellular adhesion molecule-1 (ICAM1) (Allingham et al., 2007; Turowski et al., 
2008). 
 Tight junctions are formed by the transmembrane and intracellular molecules 
such as occludin, the claudins, and junctional adhesion protein ZO-1 (Mitic and 
Anderson, 1998). On the other hand, ZO-1 plays an important role in signal 
transduction and to make a contact between occludin and the actin cytoskeleton 
(Fanning et al., 1998). 
 
 Furthermore, another type of junction, the gap junction, is formed by 
connexins (Cx). Three types of connexins (i.e., Cx43, Cx40, and Cx37) have been 
found in the endothelium. Usually, connexins are arranged in connexons, which 
serve as channels for the intercellular passage of ions and small molecules (Simon 
and Goodenough, 1998). 
 
 Contiguous to cell-cell adhesion structures, endothelial cells possess an actin-
myosin-based contractile machinery, which is an important determinant of endothelial 
barrier integrity. It maintains the retractile tension of the EC, and is involved in the 
dynamic changes of the actin cytoskeleton in response to external mechanical forces 
like shear stress. Its activity is triggered by the phosphorylation state of the myosin 
light chain (MLC), a small regulatory subunit of myosin (Wysolmerski and Lagunoff, 
1991). The imbalance between adhesive and contractile force causes gap formation 
leading to endothelial barrier failure. 
 
1.3 Endothelium Dysfunction 
 
 Endothelial dysfunction is an impairment of normal endothelial functions and 
was first described in human hypertension in 1990 (Panza et al., 1990). Afterwards, 
impaired vasodilation in hypertension has been reported by others including small 
resistance vessels (Park et al., 2001; Schiffrin et al., 2000). Impaired endothelium 
dependent vasodilation has also been described in type 1 (Beckman et al., 2003) and 
type 2 diabetes (Rizzoni et al., 2001; Schofield et al., 2002; Endemann et al., 2004), 
coronary artery disease (Monnink et al., 2002), congestive heart failure (Landmesser 
et al., 2002), and chronic renal failure (Bolton et al., 2001; Thambyrajah et al., 2000). 
 EC release vasodilator mediators such as nitric oxide (NO), Prostaglandin I2 
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and endothelium-derived hyperpolarizing factor in response to chemical and 
mechanical stimuli, including thrombin, bradykinin, blood pressure, and shear stress, 
respectively. EC also release vasoconstrictor mediators such as endothelin-1, 
angiotensin II, thromboxane A2, reactive oxygen species (ROS), and prostaglandins 
H2 to control blood pressure. 
 
 In endothelial dysfunction, there are reduced vasodilatory responses such as 
NO generation, oxidative stress, and reduced production of hyperpolarizing factor. 
Upregulation of ICAM-1, vascular cell adhesion molecule-1 (VCAM-1), E-selectin, 
generation of chemokines such as monocyte chemoattractant protein-1, and 
production of plasminogen activator inhibitor-1 participate in the initiation of the 
inflammatory process (Taddei and Salvetti, 2002). Furthermore, the free radicals are 
produced during reperfusion to activate the adhesion of neutrophils to endothelial 
cells (Thiagarajan et al., 1997). The decreased production of NO and the increased 
production of free radicals will emphasize the sticking of neutrophils to endothelial 
cells to develop neutrophil-mediated endothelial injury. Endothelial dysfunction after 
reperfusion may cause platelet aggregation and it increases the risk of thrombosis 
(Laude et al., 2001). The insufficient production of NO is also involved in the 
development of heart failure. The coronary endothelial vasodilator dysfunction leads 
to atherosclerotic disease progression. Therefore, the coronary endothelial 
vasoreactivity measurement is an important diagnostic tool to detect coronary heart 
disease (Schachinger et al., 2000). The endothelial dysfunction increases the release 
of vasoconstrictors, decreases the production of vasorelaxing agents, and the 
synthesis of dysfunctional coagulation cascades, results in the pathophysiology of 
pre-eclampsia (Roberts et al., 1989).  
 
 Vasoactive mediators such as thrombin and histamine have long been known 
to cause interendothelial gap formation and to increase endothelial permeability in 
vivo (Majno and Palade, 1961) and in vitro (Ehringer et al., 1996). Ischemia-
reperfusion injury enhances the leukocyte-endothelium interaction in postcapillary 
venules, macromolecular leakage, and ultimately the reduction of functional capillary 
perfusion (Tauber et al., 2004). Reduction in total vascular cross-sectional area is 
also linked to the swelling of the endothelial cells during reperfusion (Ward and 
McCarthy, 1995). The acute loss of endothelial barrier function during ischemia-
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reperfusion leads to the abnormal transportation of solutes and water across the 
microvasculature, resulting in the formation of tissue edema (Menger et al., 1997). 
However, the molecular mechanism that leads to an increase in permeability during 
ischemia-reperfusion is still not fully understood. 
 
1.4 Ischemia-Reperfusion Injury 
 
 Reperfusion causes damage when the blood supply returns to the tissue after 
an ischemic period, which is known as ischemia-reperfusion injury (Eltzschig and 
Collard, 2004). This restoration of blood supply causes tissue inflammation due to 
release of cytokines and neutrophil activation. Ischemia-reperfusion injury causes 
intracellular calcium overload, generation of ROS, reduced endothelial NO production 
(Ambrosio and Tritto, 1999; Lefer and Lefer, 1996), and endothelial hypermeability, 
which leads to myocardial edema (Garcia-Dorado and Oliveras, 1993; Carden and 
Granger, 2000). The release of ROS and proteolytic enzymes from activated 
leukocytes plays a vital role in the damage of myocytes and vascular cells (Jones 
and Lefer, 2000). However, postischemic swelling of the myocardium has also been 
observed in saline-perfused hearts (Di Napoli et al., 2001), indicating that there is a 
leukocytes-independent mechanism leading to edema formation. In line with that, 
Schäfer et al. (2003) and Gündüz et al. (2010) showed that endothelial barrier 
dysfunction may be induced due to an activation of the contractile apparatus and 
distortion of cell–cell adherens junctions, leading to intercellular gap formation.  
 However, the mechanism of reperfusion-induced injury is not fully understood. 
The understanding of the pathophysiology of reperfusion injury is one of the 
important challenges in designing novel therapeutic approaches in acute coronary 
disease. Therefore, it is important to analyze the mechanism of activation of the 
contractile machinery of EC as well as loss of cell-cell adhesion proteins during 
ischemia-reperfusion. 
 
1.5 Endothelial Adherens Junction Proteins 
 
 The intercellular junctions between endothelial cells control the movement of 
solutes between blood and tissues. The interaction of adherens junction proteins with 
the actin cytoskeleton is important for stabilization of junctions. The adherens junction 
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protein VE-cadherin has extracellular and cytoplasmic domains. The cytoplasmic 
domain binds to three related catenins: β-catenin, p120, and γ-catenin (plakoglobin). 
β-catenin binds to α-catenin, which in turn binds to the actin cytoskeleton; this binding 
is important for endothelial cell barrier function (Yamada et al., 2005 Vestweber, 
2008). Tyrosine phosphorylation of junctional proteins like cadherins and catenins is 
an indicator of junctional disassembly (Young et al., 2003). Disruption of homophilic 
binding of VE-cadherin to catenins increases endothelial permeability to 
macromolecules (Hordijk et al., 1999). 
 
1.6 Endothelial Actomyosin Cytoskeleton 
 
 There are three basic mechanisms involved in inflammatory conditions that 
lead to endothelial barrier dysfunction: (I) cytoskeletal protein reorganization, i.e. the 
rearrangement of cortical actin into cytosolic stress fibers; (II) activation of the 
contractile machinery; (III) disassembly of adhesion junctions induced by 
phosphorylation of cell adhesion molecules. This leads to a dissociation of 
intracellular regulatory proteins like β-catenin from VE-cadherin, which results in its 
internalization or degradation of adherens junctions. The fundamental parts of the 
endothelial cytoskeleton are actin filaments (microfilaments), intermediate filaments, 
and microtubules, which are responsible to maintain cell shape (Chang and 
Goldman, 2004; Revenu et al., 2004; Dudek and Garcia, 2001). The dynamic 
equilibrium of actin cytoskeleton between polymerization and de-polymerization 
depends on the cellular demand. Normally, there is an equal balance between the 
amount of G-actin and F-actin (Stossel et al., 1985). Actin polymerization is 
necessary for the formation of F-actin, which is a basic structural unit for actin 
cytoskeletal. Actin bundles organize into three structures, the membrane skeleton, 
cortical actin rim at the cell periphery and stress fibers. The membrane skeleton and 
stress fibers are made up of short F-actin filaments (Cramer et al., 1997). Stress 
fibers are contractile actomyosin structures and play an important role in cell 
contraction (Hotulainen and Lappalainen, 2006); and interendothelial cell gap 
formation (Dudek and Garcia, 2001). 
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1.7 Endothelial Contractile Apparatus 
 
 The endothelial cell contractility is regulated by actomyosin interactions that 
require actin polymerization and phosphorylation of MLC. The MLC phosphorylation 
is controlled by the activity of two key enzymes, Ca2+/calmodulin (CaM)-dependent 
myosin light chain kinase (MLCK) and myosin light chain phosphatase (MLCP) (Verin 
et al., 1995).  
 
 
1.7.1 Role of MLC Phosphorylation 
 
 Myosins are contractile proteins and are one of the most abundant proteins in 
cells. On the basis of their head domain structure, myosins can be grouped into 
different categories (Weiss and Leinwand, 1996). The most important class of 
myosins is myosin II, which is an actin-binding protein, originally identified in muscle, 
but also found in non-muscle cells. It is made up of two heavy chains, containing the 
head and tail domain, two essential and two regulatory MLC. In non-muscle cells, 
myosin II activity is controlled by the phosphorylation level of the regulatory MLC. It is 
reported that MLCK and Rho-associated protein kinase (ROCK) can directly 
phosphorylate MLC at Thr18 and Ser19 (Hirata et al., 2009; Garcia et al., 1995). It 
can also be phosphorylated at Ser1/2 and Thr9 (Yamakita et al., 1994). MLC 
phosphorylation at Ser19 is assumed to promote the contractility and stability of 
actomyosin (Sellers, 1991; Trybus, 1991). This concept is supported by Haeberle et 
al. (1988) and Umemoto et al. (1989) showing that phosphorylation of MLC at Ser19 
starts actomyosin interaction and generates maximum force in permeabilised smooth 
muscle cells. Additional phosphorylation at Thr18 does not further increase the 
sliding speed of actin filaments produced by interaction with myosin in in vitro assays. 
 
 Actomyosin interactions play an important role in cell structure, contraction, 
adhesion, stress fibre formation, and the ensuing EC barrier dysfunction. MLCP 
dephosphorylates MLC, causing cell relaxation and barrier stabilization (Verin et al., 
1995; Totsukawa et al., 2000). 
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1.7.2 Role of Myosin Light Chain Kinase (MLCK) 
 
 It has been shown that EC express a MLCK isoform of approximately 214 kDa 
which has a much higher molecular weight then the 113 kDa isoform found in smooth 
muscle cells (Garcia et al., 1997; Lazar and Garcia, 1999). Both isoforms share the 
MLC binding site, the catalytic and Ca2+/CaM regulatory motifs. However, the high-
molecular EC-MLCK additionally possesses a unique 922-amino-acid domain at its 
NH2-terminus, which contains multiple regulatory serine and tyrosine phosphorylation 
sites. 
 
 The MLCK-mediated actomyosin contraction is correlated with cell function, 
morphology, and motility. Activation of MLCK elevates MLC phosphorylation, 
cytoskeleton contraction, stress fibre formation, and intercellular gap formation 
(Tinsley et al., 2000). The MLCK inhibitor ML-7 enhances the basal barrier function 
and considerably reduces agonist-induced hyperpermeability in isolated-perfused 
coronary venules (Yuan et al., 1997). Inflammatory mediator such as thrombin 
increases EC permeability, which can be attenuated by the inhibition of MLCK activity 
(Garcia et al., 1995). ML-7, a cell-permeable inhibitor of MLCK, also reduces gap 
formation during reoxygenation in a model of endothelial monolayers (Schäfer et al., 
2003). Thus, under physiological conditions MLCK is an important regulator for 
solutes, macromolecules and blood cells which pass the endothelium on a 
paracellular route. Under pathophysiological conditions, however, it becomes a 
critical determent for hyperpermeability (Shen et al., 2010). 
 
1.7.3 Role of Myosin Light Chain Phosphatase (MLCP) 
 
 In smooth muscle cells, as well as in endothelial cells, MLCP is a holoenzyme 
complex composed of protein phosphatase 1 (the catalytic subunit PP1), myosin 
phosphatase targeting subunit (the regulatory subunit MYPT1), and a smaller subunit 
of 20 kDa whose function is still unknown (Alessi et al., 1992; Shimizu et al., 1994).  
 
 The PP1 is a serine-threonine phosphatase that regulates different cellular 
processes such as protein synthesis, cell cycle progression, proliferation, 
carbohydrate metabolism, and muscle relaxation. It has a molecular weight of 
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approximately 38 kDa and consists of three isotypes, PP1α, PP1β/δ, and PP1γ 
(Shima et al., 1993). Principally, PP1 can dephosphorylate a multitude of substrates. 
Its specificity results from its binding to a regulatory subunit, which specifically 
recruits the catalytic subunit to its substrate. Therefore, the regulatory subunits are 
unrelated, but share the same PP1-binding sequence known as the RVxF motif 
(Terrak et al., 2004). In endothelial cells, as well as in smooth muscles cells, MYPT1 
binds PP1δ to form the active MLCP holoenzyme complex which dephosphorylates 
MLC (Verin et al., 2000; Härtel et al., 2007). Two binding sites of PP1 on MYPT1 
have been reported: a strong binding site in the N-terminal region (the so called N-
terminal peptide from amino acid 1 to 38), and a weak site in the C-terminal half of 
the ankyrin repeats (Hartshorne et al., 1998). In addition to that, MYPT1 is essential 
for MLCP activity because PP1 alone has low phosphatase activity towards 
substrates like MLC (Hirano et al., 1997; Johnson et al., 1997). 
 
 Different isoforms of MYPT have been identified, such as MYPT1, MYPT2, 
MBS85, MYPT3, and TIMAP (Ito et al., 2004). MYPT1 is also called M110, myosin 
binding subunit (MBS), or M130/M133. Originally it was cloned from chicken gizzard 
and rat aorta (Shimizu et al., 1994; Chen et al., 1994), but later, Hirano et al. (1997) 
found MYPT1 also expressed in EC from porcine aorta. As other regulatory subunits, 
MYPT1 contains the PP1c-binding RVxF motif followed by 7-8 ankyrin repeats in the 
N-terminal region. MYPT1 from smooth muscle cells directly binds to myosin via its 
C-terminal region (Hirano et al., 1997; Matsumura and Hartshorne, 2008). MYPT1 
does not only confer substrate specificity but also a site of MLCP regulation. It is well 
established that MYPT1 possess two important inhibitory phosphorylation sites, 
threonine (Thr) 850 and Thr696 (for sequence in smooth muscle cells). RhoA 
associated Rho kinase (ROCK) was the first kinase shown to phosphorylate MYPT1 
at Thr850 site, which is present in myosin-binding domain to induce dissociation of 
MLCP from myosin (Velasco et al., 2002), while phosphorylation at Thr696 leads to 
inhibition of MLCP without complex dissociation (Feng et al., 1999; Ito et al., 2004). 
Since then kinases have been reported phosphorylating MYPT1 at its inhibitory sites, 
like ROCK (Kimura et al., 1996; Feng et al., 1999) ZIP kinase (ZIPK) (MacDonald et 
al., 2001). The thiophosphorylation of MYPT1 caused the decrease in the activity of 
the enzyme and myosin light chain phosphorylation in smooth muscle cells. It 
indicates that the phosphorylation and dephosphorylation of this subunit is important 
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for the regulation of smooth muscle contraction (Trinkle-Mulcahy et.al., 1995). 
Furthermore, PKA or PKG have been shown to phosphorylate MYPT1 at Ser695 
causing MLCP activation or preventing its inhibition (Wooldridge et al., 2004; 
Nakamura et al., 2007).  
 
 In addition to MYPT1 phosphorylation, MLCP activity is modulated by a group 
of small molecular weight regulatory proteins, which directly interact with the PP1 
catalytic subunit. The PKC-potentiated inhibitory protein of 17 kDa (CPI-17) is of 
special interest in the context of this study. There are also CPI-17 homologues, PHI 
(Eto et al., 1999), KEPI (Liu et al., 2002), and GBPI (Liu et al., 2004) in the human 
genome. Each CPI-17 family member contains a PP1 inhibitory domain, where the 
sequences are >41 % identical to CPI-17 (Eto et al., 1999). CPI-17 is targeted by a 
variety of kinases. In its phosphorylated form CPI-17 binds to PP1 leading to an 
inhibition and disassembly of the MLCP holoenzyme. 
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Figure 1.1: The activity of myosin light chain phosphatase (MLCP) is inhibited via 
phosphorylation of MYPT1 and CPI-17 leading to an increase myosin light chain 
(MLC) phosphorylation and contractile activation.  
 
1.8 Role of Rho-Kinase 
 
 Two isoforms of ROCK have been identified in mammals: ROCKI and ROCKII 
(Leung et al, 1995; Matsui et al., 1996).  In all cells of the cardiovascular system 
ROCK is controlled by members of Rho-GTPases, particularly RhoA, and is a central 
intracellular effector of a multitude of mediators, activating cells via G-protein coupled 
receptors (Somlyo and Somlyo, 2000). Under physiological conditions ROCK is 
involved in smooth muscle contraction and the ensuing regulation of vascular tone. 
Furthermore, it is an important determinant for dynamic changes of the cell 
cytoskeleton, adhesion structures, and triggers cell physiological processes like 
migration and proliferation (Kaibuchi et al., 1999). Pathophysiological derailment of 
ROCK activity can cause vasoconstriction up to vasospasms or proliferation of 
smooth muscle cells of the media. Accordingly, a systemic increase of blood 
pressure up to hypertension, vascular remodelling and myocardial hypertrophy has 
been associated with a persistent enhanced ROCK activity (Shimokawa and 
Takeshita, 2005).  This concept is supported by experimental and clinical studies 
showing that inhibition of ROCK can blunt these diseases (Sawada et al., 2000; 
Mallat et al., 2003).  
 
 In EC activation of RhoA by thrombin leads a ROCK-mediated inhibition of 
MLCP, an increase in MLC phosphorylation, activation of the contractile apparatus, 
stress fibre formation, and increased permeability (Essler et al., 1998; van Nieuw 
Amerongen et al., 1998). Rho-kinase is activated by hypoxia induces MLC 
phosphorylation that leads to pulmonary vasoconstriction in cultured pulmonary 
arterial smooth muscle cells and isolated rat pulmonary artery. The Rho-kinase 
inhibitor Y-27632 abolishes hypoxia-induced pulmonary contraction, indicating that 
Rho-kinase plays an important role in hypoxia-induced pulmonary vasoconstriction 
(Wang et al., 2001). Accordingly, Y-27632, which specifically blocks ROCK activity 
(Ishizaki et al., 2000), lead to MLC phosphorylation, stress fiber formation, and 
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attenuated thrombin-induced permeability (Carbajal et al., 2000; van Nieuw 
Amerongen et al., 2000a).  
 
1.9 Role of Protein Kinase C 
 
 Protein kinases C (PKCs) are a family of serine-threonine protein kinases and 
their activities are regulated by Ca2+, diacylglycerol (DAG), and phospholipids. PKC 
has been reported to regulate different cellular functions such as proliferation and 
differentiation (Nishizuka, 1984). The various isoforms of PKC have been divided into 
3 classes on the basis of their structure, activation, and substrate specificity (Parekh 
et al., 2000). The conventional or classic PKCs [alpha (α), beta (ß), gamma (γ)] are 
Ca2+-dependent and are regulated by DAG. The novel PKCs [delta (δ), epsilon (ε), 
eta (η), theta (θ)] are also regulated by DAG but are Ca2+-independent. The atypical 
PKCs [zeta (ζ), iota (ι), lambda (λ)] are independent of both Ca2+ and DAG. The 
activity of PKC isoforms depend on their phosphorylation status (Mitchell et al., 1989; 
Pears et al., 1992; Sonnenburg et al., 2001). The PKC isoforms have four conserved 
domains (C1–C4) and five variable domains (V1–V5) (Soderling, 1990). 
 
 PKC plays a vital role in the endothelial dysfunction in response to different 
inflammatory mediators, and targeting this signaling molecule with specific inhibitors 
may constitute an effective therapy for treatment. The regulatory and catalytic 
domains are important pharmacological targets in designing inhibitors, and many 
inhibitors have already been reported, e.g. calphostin C and sphingosine, that 
interact with the regulatory domain (Kobayashi et al., 1989; Hannun et al., 1986). 
Staurosporine and bisindolylmaleimide (BIM) block PKC activity by interaction with 
the ATP binding site (Tamaoki et al., 1986; Toullec et al., 1991). The activated PKC 
by DAG increases both MLC phosphorylation at PKC-specific sites and force 
development due to inhibition of MLC dephosphorylation rather than stimulation of 
MLC phosphorylation (Masuo et al., 1994; Ikebe and Brozovich, 1996). 
 
 PKC was the first kinase studied in detail during ischemia-reperfusion. The 
activation and translocation of PKC to the membrane during ischemia was initially 
analyzed by a protein kinase C activity assay of the cytosol and membrane fractions 
of hearts exposed to ischemia or ischemia-reperfusion (Prasad and Jones, 1992). 
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The ischemic translocation was not altered by reperfusion. PKC α, δ, and ε 
translocation to the membrane and nuclear fractions was reported in rat hearts during 
ischemia (Yoshida et al., 1996). The translocation of PKC α, ε, and ι was also 
observed in a rat heart model during myocardial ischemia (Albert and Ford, 1999). 
 
 Previously, the crucial role of PKC has been reported in post-ischemic 
endothelium dysfunction by increased production of superoxides in guinea-pig hearts 
(Maczewski and Beresewicz, 2000). PKC are activated in response to several 
inflammatory mediators such as thrombin, bradykinin, and platelet activating factor 
(Yuan, 2002) and it has been revealed that PKC causes endothelial barrier 
dysfunction induced by these mediators (Murray et al., 1991; Ramirez et al., 1996; 
Sandoval et al., 2001) but the molecular mechanism involved in endothelial 
dysfunction by PKC is not fully understood. The underlying study investigated the role 
of PKC signalling and the role of VE-cadherin at cell-cell contacts in the regulation of 
endothelial barrier functions. 
 
 Many studies have shown that in smooth muscle cell PKC is involved in the 
regulation of MLC phosphatase in response to various agonists (Somlyo and Somlyo, 
2003). It has been shown that histamine induces MLC phosphorylation, partial 
inhibition of MLC phosphatase, and disruption of the actin cytoskeleton in corneal 
endothelium through Ca2+ and PKC mediated pathways. This is further influenced by 
CPI-17 phosphorylation (Srinivas et al., 2006). CPI-17 is phosphorylated by PKCα 
and PKCδ isoforms and the phosphorylated form inhibits PP1Cδ, the catalytic subunit 
of MLC phosphatase (Eto et al., 2001). This led to the assumption that the PKC-
induced activation of the contractile machinery and increased in permeability may be 
explained by a PKC/CPI-17-mediated inhibition of MLCP. 
 
1.10 Expression and Regulation of CPI-17 
 
 CPI-17 is a soluble globular protein and is described to be an endogenous 
inhibitor of MLCP (Eto et al., 1995). Two isoforms of CPI-17 have been reported, 
CPI-17α (147 residues, 16.7 kDa) and CPI-17β (120 residues, 13.5 kDa). The three-
dimensional structure of unphosphorylated CPI-17 reveals that it is composed of a 
four-helix bundle followed by a loop structure (the inhibitory P-loop) at the N-
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terminus. The critical phosphorylation site (Thr38) is present in the P-loop structure, 
in a cavity between helices (Ohki et al., 2001). CPI-17 was initially discovered in 
smooth muscle tissues (Eto et al., 1997), and the expression level is high in tonic 
muscles, but lower in phasic muscles. The PKC induced contraction depends on the 
expression level of CPI-17 in each tissue (Woodsome et al., 2001). The expression 
level of CPI-17 was also analyzed in embryonic smooth muscle tissues and arterial 
neointimal lesions. It is highly expressed in mature smooth muscle cells, but the 
expression level is different under pathological conditions (Kim et al., 2009). 
Moreover, undetectable level of CPI-17 was observed in arterial smooth muscle from 
chicken and it produces an insignificant level of the force through G-protein-mediated 
signals (Kitazawa et al., 2004). CPI-17 expression is also found in platelets 
(Watanabe et al., 2001) and brain tissues (Dubois et al., 2003). CPI-17 
phosphorylation leads to pulmonary hypertension under hypoxia (Dakshinamurti et 
al., 2005). CPI-17 higher expression and activation has been observed in airway-
hyper-responsiveness that is associated with heightened airway resistance and 
inflammation is a characteristic feature of asthma (Sakai et al., 2005). Thus, the 
expression level of CPI-17 is an essential determinant for MLC phosphorylation and 
smooth muscle contraction. Further, it was shown that upregulation of CPI-17 and 
Rho-kinase mediated Ca2+ sensitization leads to high MLC phosphorylation level, 
slow relaxation in detrusor smooth muscle, and bladder dysfunction in diabetic 
animals (Chang et al., 2006). 
 
 Several phosphatases and kinases control the phosphorylation level of CPI-
17. Activation of PKC (Eto et al., 1995), ROCK (Koyama et al., 2000), protein kinase 
N (Hamaguchi et al., 2000), and ZIP-like kinase (MacDonald et al., 2001), integrin-
linked kinase (Huang et al., 2006) induces CPI-17 phosphorylation on Thr38 in vitro. 
PKC α and δ are the dominant kinases that phosphorylate CPI-17 (Eto et al., 2001). 
CPI-17 is also phosphorylated by PKC α, ε, λ, and ζ, isoforms (Zemlickova et al., 
2004). In addition to this, zipper-interacting kinase (MacDonald et al., 2001) and p21-
activated kinase (Takizawa et al., 2002) are directly involved to phosphorylate CPI-17 
at Thr38. Activation of G-protein-coupled receptors induces a rapid activation of Ca2+-
dependent PKC, which in turn phosphorylate CPI-17 leading to an inhibition of 
MLCP. Maneuver elevating the cellular levels of cAMP (Aslam et al., 2010) or cGMP 
reduce phosphorylation of CPI-17 (Etter et al., 2001). A similar effect can be 
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observed in presence of cGMP analogues (Bonnevier and Arner, 2004). In addition, 
phosphatase 2A and 2C are also attributed to dephosphorylate CPI-17 (Takizawa et 
al., 2002), indicating the fact that several phosphatases regulate CPI-17 
phosphorylation. 
 
 CPI-17 phosphorylation at Thr38 results in an inhibition of MLCP activity 
whereas dephosphorylation causes relaxation of smooth muscle cells. Agonists like 
histamine, phorbol ester, and phenylepinephrine induce phosphorylation of CPI-17 at 
Thr38 (Kitazawa et al., 2000). Histamine-induced phosphorylation of CPI-17 is 
catalysed by PKC and  isoforms (Eto et al., 2001). The current concept is that 
phosphorylated CPI-17 elicits a conformational change and directly binds at the 
active site of PP1 catalytic subunit and inhibits MLCP (Ohki et al., 2003). 
Furthermore, there is accumulating evidence that CPI-17 plays an important role in 
cytoskeletal reorganisation under cell stress.  It has been shown that overexpression 
of CPI-17 in fibroblasts cause abnormal accumulation of cortical F-actin fibres and 
MLC phosphorylation (Eto et al., 2001). Kolosova et al. (2004) demonstrated that 
PKC/CPI-17 pathway may be involved in the regulation of endothelial cytoskeleton, 
focal adhesions, and MLC phosphorylation in response to histamine. Recently, it has 
been shown that stimulation of the cAMP/PKA-signalling pathway in endothelial cells 
reduces the phosphorylation level of CPI-17 in EC from human umbilical veins in 
analogy to the intact arterial smooth muscle (Aslam et al., 2010).  
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1.11 AIMS OF THE PRESENT PROJECT 
 In the present study, the role of the contractile machinery in the remodeling of 
the endothelial cytoskeleton and disruption of the adherens junctions during 
reperfusion is studied. The integrity of endothelium barrier is maintained by 
contractile forces and junctional proteins that make a contact between adjacent cells. 
Under pathological conditions, the loss of this barrier integrity promotes actin-myosin 
interactions and the opening of intercellular junctions that leads to hyperpermeability. 
Endothelial hyperpermeability contributes in the progression of different diseases. It 
was hypothesized that the increased permeability is associated with alteration in the 
structure and organization of the cytoskeletal junctional complexes in response of 
reperfusion. The physiological role of actin-myosin interactions in cytoskeletal 
remodelling during reperfusion is not fully understood. The aims of study were to 
investigate: 
1. the potential mechanism of reperfusion-induced activation of the contractile 
machinery and increased intercellular gap formation, 
2. the role of MLCK and MLCP in the regulation of the MLC phosphorylation status 
during reperfusion, 
3. the role of Rho-kinase and PKC in reperfusion-induced inhibition of MLCP, 
4. the functional role of CPI-17, an endogenous inhibitor of MLCP, on reperfusion-
induced barrier failure, 
5. the effect of reperfusion on localization of adherens junctions proteins VE-
cadherin and β-catenin, 
6. the role of the actin cytoskeleton in reperfusion-induced barrier failure. 
 To achieve these aims, underlying experiments were performed with an 
established cultured model of porcine aortic endothelial cells (PAEC) and human 
umbilical vein endothelial cells (HUVEC) during reperfusion after simulated ischemia. 
In pilot sets of experiments, PAEC were exposed to 45 min of simulated ischemia 
(Po2 < 1 mmHg, pH 6.4) followed by 45 min of reperfusion (Po2 = 100 mmHg, pH 
7.4). The phosphorylation status of contractile proteins was analyzed in Western 
blotting. Pharmacalogical inhibitors were used to identify the signaling cascades to be 
involved in reperfusion-induced barrier failure. The functional assay was performed 
by measuring macromolecular permeability across endothelial monolayers in CPI-17 
downregulated cells. Distortion of adherens junctions proteins and actin 
rearrangement were visualized by immunocytochemistry. 
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2 MATERIALS 
 
2.1 Chemicals and Reagents 
 
Acrylamide Roth, Karlsruhe 
Agarose Invitrogen, Paisley, United Kingdom 
6-Aminohexanoic acid Merck-Schuchardt, Hohenbrunn 
APS Serva, Heideberg 
Benzonase Merck, Darmstadt 
Bisacrylamide Roth, Karlsruhe 
Bromphenol blue Sigma, Deisenhofen 
BSA Sigma, Deisenhofen 
Calyculin A Calbiochem, Bad Soden 
Calcium chloride Merck, Darmstadt 
Collagenase PAA Laboratories, Pasching, Austria 
Complete® inhibitor cocktail Roche, Mannheim 
CPI-17 siRNA Qiagen  Hilden 
DMSO Sigma, Deisenhofen 
DTT Sigma, Deisenhofen 
EC Oxyrase Oxyrase, Mansfield, USA 
EDTA-Sodium chloride Sigma, Deisenhofen 
Endothelial Growth Medium Kit PromoCell, Heidelberg 
Ethanol Riedel de Haёn, Seelze 
FCS PAA Laboratories, Pasching, Austria 
FuGENE 6  Roche, Mannheim 
Glucose Merck, Darmstadt 
Glycine Roth, Karlsruhe 
Glycerol (100%) Roth, Karlsruhe 
HBSS PAA Laboratories, Pasching, Austria 
HEPES Roth, Karlsruhe 
High molecular weight standard Sigma, Deisenhofen 
Low molecular weight standard Sigma, Deisenhofen 
Potassium chloride Merck, Darmstadt 
Potassium dihydrogen phosphate Merck, Darmstadt 
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Medium 199/Earl`s Salts Gibco BRL, Eggenstein 
Magnesium chloride Fluka, Neu-Ulm 
Magnesium sulfate Merck, Darmstadt 
Methanol Riedel de Haёn, Seelze 
Mercaptoethanol Merck-Suchard, Hohenbrunn 
Millipore water Millipore, Eschborn 
Opti-MEM I  Gibco Life Technologies GmbH, Darmstadt 
Sodium flouride Merck, Darmstadt 
Sodium chloride Roth, Karlsruhe 
Sodium bicarbonate  Merck, Darmstadt 
Di-Sodium hydrogen phosphate  Roth, Karlsruhe 
Sodium hydroxide Roth, Karlsruhe 
Neonatal Calf Serum PAA Laboratories, Pasching, Austria 
Paraformaldehyde Merck, Darmstadt 
Penicillin-streptomycine Gibco BRL, Eggenstein 
Ponceau S Solution Serva, Heidelberg 
Sodium dodecyl sulphate Merck, Darmstadt 
N2 gas Air Liquid, Krefeld 
Sodium flouride Merck, Darmstadt 
TEMED Sigma, Deisenhofen 
Tween 20 Amersham, Braunschweig 
Tris Roth, Darmstadt 
Triton X-100 Serva, Heidelberg 
Trypsin EDTA solution Biochrom AG, Berlin 
 
2.2 Pharmacalogical Inhibitors 
 
ML-7 Alexis, Lörrach 
BIM Calbiochem, Bad Soden 
Y-27632 Alexis, Lörrach 
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2.3      Antibodies 
 
 
 
2.4      siRNA 
 
Primary Antibodies  
Anti-CPI-17; rabbit IgG Upstate, Charlottesville, USA 
Anti-Phospho-CPI-17; rabbit IgG Upstate, Charlottesville, USA 
Anti-MLC; Clone MY-21; mouse IgM Sigma, Steinheim 
Anti-Phospho–MLC; rabbit IgG Cell Signalling, Danvers, USA 
Anti-MYPT1; rabbit gG Upstate, Charlottesville, USA 
Anti-Phospho-MYPT850; rabbit IgG Upstate, Charlottesville, USA 
Anti-RhoA; mouse IgG Santa Cruz Biotechnology, Heidelberg 
Anti-Actin;  Clone AC-40; mouse IgG Sigma, Deisenhofen 
Anti-Vinculin;  Clone hVIN-1; mouse IgG Sigma, Steinheim 
Anti-α-Tubulin;  mouse IgG Calbiochem, Darmstadt 
Anti VE-Cadherin (C-19); goat IgG Santa Cruz Biotechnology, Heidelberg 
Anti-Catenin-beta; TRITC BD Biosciences, Heidelberg 
Anti-phalloidin; TRITC Sigma, Steinheim 
Secondary Antibodies  
Anti-rabbit; IgG; HRP-Conjugate; from donkey Upstate, Charlottesville, USA 
Anti-mouse; IgG; HRP-Conjugate; from sheep BD Biosciences, Heidelberg 
Anti-mouse; IgM; HRP-Conjugate; from goat Sigma, Steinheim 
Anti-goat; IgG; TRITC (Red) Invitrogen, Karlsruhe 
Anti-mouse; IgG; Alexa fluor 488(R) donkey 
(Green) 
Invitrogen, Karlsruhe 
Gene  Sequence  
CPI-17 siRNA 5'-ACCUGUCGAGGACUUCAUCdTdT-3' Qiagen, Hilden 
 3'-GAUGAAGUCCUCGACAGGUdTdT-5'  
neg siRNA  Qiagen, Hilden 
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2.5      Laboratory Instruments 
 
Material for cell culture: 
CCD camera  Bio Rad Laboratories, Hercules, USA 
Culture dishes Becton-Dickinson, Heidelberg 
Demineralisation unit Millipore, Eschborn 
Electroblot chamber Biotec-Fischer, Reiskirchen 
Electrophoresis apparatus Biometra, Göttingen 
Electrophoresis chamber Biotec-Fischer, Reiskirchen 
Filter paper Biotec-Fischer, Reiskirchen 
Glas coverslips Menzel, Braunschweig 
Glass articles Schott, Mainz 
Hamilton syringe Hamilton, Bonaduz,Switzerland 
Incubator Heraeus, Hanau 
LSM-510 confocal microscope Carl-Zeiss, Heidelberg 
Magnet stirrer Jahnke und Kunkel, Staufen 
Magnetic rack Dynalbiotech ASA Oslo, Norway 
Microscope Olympus, Japan 
Neubauer-chamber Superior, Marienfeld 
Nitrocellulose membrane Schleicher und Schuell, Dassel 
pH-Meter WTW-Weilheim 
Pipette tips Eppendorf Netheler-Hinz, Hamburg 
Pipettes Eppendorf-Netheler-Hinz, Hamburg 
Polycarbonate Membrane Transwell Inserts    Corning Life Sciences, Lowell, USA 
Power supply Biometra, Göttingen 
Preparation instruments Aeskulab, Heidelberg 
Rubber policeman Becton-Dickinson, Heidelberg 
Shaker Biometra, Göttingen 
Sterile bench Heraeus, Hanau 
Sterile filter (0.2 µm) Sartorius, Göttingen 
Sterile pipettes Becton-Dickinson, Heidelberg 
Table centrifuge Hereaus, Hanau 
Tissue chopper Harvard Apperatus, March-Hugstetten 
Tubes Eppendorf-Netheler-Hinz, Hamburg 
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Vortex Heidolph, Kelheim 
Water bath Julabo, Seelbach 
 
2.6 Softwares 
 
Microsoft Excel 2000 Microsoft Corp, USA 
Microsoft Word 2000  Microsoft Corp, USA 
Microsoft Windows XP Microsoft Corp, USA 
Quantity One analysis software Bio-Rad Laboratories, Hercules, USA 
LSM 510 confocal microscope Carl-Zeiss, Heidelberg 
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3  METHODS 
 
 3.1 Isolation and cell culture 
 
Preparation of porcine aortic endothelial cells (PAEC) 
 
 Endothelial cells from porcine aorta were isolated as previously described 
(Spahr and Piper, 1990). Porcine aortas were freshly obtained from the 
slaughterhouse and kept in 0.9% (wt/vol) NaCl solution until final preparation. 
 
 In the first step, aortas were freed from adventitial tissue, opened by a 
longitudinally cut, mounted onto a board, and rinsed with 0.9% (wt/vol) NaCl solution 
to flush the intima. Finally, endothelial cells of the upper layer of intima were gently 
scratched off with a scalpel and transferred into 40 ml of pre-warmed M199 medium. 
The suspended cells were centrifuged at 260 x g at room temperature for 8 minutes, 
the supernatant was removed and the pellet was dissolved in fresh cell culture 
medium. Afterwards, the cells were seeded onto primary cell culture dishes which, 
contain cell culture medium 199 supplemented with 5% (vol/vol) penicillin/ 
streptomycin and 10% (vol/vol) NCS. Then cells were cultivated at 37 °C and 5% 
CO2 in humidified environment for 3-4 hours. Thereafter, cells were extensively rinsed 
with pre-warmed HEPES (pH 7.4) to remove cell debris and non-adherent cells. Then 
adherent endothelial cells were cultured in 15 ml fresh cell culture medium. The next 
day, cell culture medium was replaced by medium 199 supplemented with 2% 
(vol/vol) penicillin/streptomycin and 10% (vol/vol) NCS. 
 
Cell culture medium: 
 
 M199 medium        x ml 
 NCS (vol/vol)       10% 
 Penicillin/streptomycin (100 lU/ml, 100 µg/ml) (vol/vol)   2% 
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M199 medium:  (pH 7.4) 
 
 Medium 199 / Earl’s salt     9.62 g/l 
 HEPES       15 mM 
 NaHCO       24 mM 
 
HEPES/Tyrode’s buffer (HBS):  (pH 7.4) 
 NaCl        125 mM 
 KCl        2.6 mM 
 KH2PO4       1.2 mM 
 MgSO4       1.2 mM 
 HEPES       25 mM 
 
Preparation of human umbilical vein endothelial cells (HUVEC) 
 
 Endothelial cells from human umbilical veins were isolated as previously 
described (Jaffe et al., 1973). The umbilical vein was cannulated and perfused with 
HBSS to remove traces of blood, and was finally filled with collagenase solution 
(0.2%; wt/vol), using a 30-ml syringe. After 20-30 minutes of incubation at 37 °C, the 
collagenase solution containing endothelial cells was gently flushed out from the vein 
with 30 ml of HBSS containing 3% (vol/vol) FCS, to inactivate the collagenase. The 
cell suspension was collected in a 50 ml falcon tube and centrifuged for 5 minutes at 
260 x g. The supernatant was removed and cells were resuspended in culture 
medium supplemented with 0.1% (vol /vol) gentamycin. The cells were seeded on 3-
4 primary 10-cm cell culture dishes and cultured in an incubator (37 °C, 5% CO2) for 
2 hours. Afterwards, cells were washed with pre-warmed HBSS to remove 
erythrocytes and non-adherent cells. Adherent cells were continued to incubate in 
fresh cell culture medium in an incubator. The next day, medium was replaced with 
fresh endothelial cell culture medium. 
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Collagenase solution 
 
 HBSS        xml 
 Collagenase II (293 Units/mg) (wt/vol)   0.025 % 
MgCl2        0.5 mM  
CaCl2        1.5 mM   
 
Endothelial cell culture medium 
 
 Endothelial cell basal medium (PromoCell) supplemented with following 
reagents: 
 FCS (vol/vol)      10% 
 Endothelial cell growth supplement/Heparin (wt/vol) 0.4% 
 Hydrocortisone (wt/vol)     0.1% 
 bFGF (wt/vol)      1 ng/ml 
 hEGF (wt/vol)      0.1 ng/ml 
 Penicillin/streptomycin (vol/vol)    2%  
 
3.2 Subcultivation of endothelial cells 
 
 Confluent cultures of primary endothelial cells were washed with pre-warmed 
HBSS and subsequently trypsinized in 3 ml of trypsin/EDTA solution (composition: 
137 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 8 mM Na2HPO4, pH 7.4, 0.05% (wt/vol) 
trypsin and 0.02% (wt/vol) EDTA). Detached cells were collected into cell culture 
medium and seeded on cell culture dishes at a density of 2.2 x104 cells/cm2.  For 
determination of albumin permeability cells were seeded on round polycarbonate 
membrane transwell inserts. For immunostaining, cells were seeded on 2.5 cm glass 
cover-slips. Experiments were performed with confluent endothelial monolayers. 
 
3.3 Experimental protocol for ischemia-reperfusion 
 
 Monolayers of endothelial cells (80-90% confluence) were exposed to 45 min 
of simulated ischemia (Po2 < 1 mmHg, pH 6.4) followed by 15, 30 or 45 min of 
reoxygenation (Po2 = 100 mmHg, pH 7.4). Cells were placed on a heating plate at 37 
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°C and culture medium was replaced with HBSS for 20 minutes to allow the cells to 
adapt to the incubation conditions (pre-incubation period). Then the cells were 
exposed to anoxic medium containing 1 U/ml EC-Oxyrase, an oxygen consuming 
enzyme from bacteria, which reduced the Po2 in the medium within 1 min below 1 
mmHg and maintains it at that low level throughout the ischemic period. Afterwards 
cells were reoxygenated by change to normoxic medium. In pilot experiments the 
time course of Po2 during ischemia and reoxygenation was verified by a 
polagrographic oxygen electrode. As controls, EC monolayers were incubated at 
normoxic conditions for 90 min in normoxic medium. In a set of experiments EC were 
reoxygenated in presence of 10 µM ML-7 (myosin light chain kinase inhibitor), 8 µM 
bisindolylmaleimide (BIM, a protein kinase C inhibitor), or 20 µM Y-27632 (a ROCK 
inhibitor), respectively. In pilot experiments the minimum effective concentration of 
these inhibitors were determined, and stock solutions of Y-27632, BIM, and ML-7 
were prepared in DMSO immediately before use. The same final concentration of 
DMSO was included in all respective control samples, final concentration 0.1 % 
(vol/vol). 
 
 
 
Anoxic Medium (pH 6.4) 
 
 NaCl       137.8 mM 
CaCl2       1.3 mM 
 KCl       2.6 mM 
 KH2PO4      1.2 mM 
 MgSO4 x 7H2O     1.2 mM 
HEPES      22 mM 
 
29 
 
Normoxic Medium (pH 7.4) 
 
 NaCI       137.8 mM 
 CaCl2       1.3 mM  
 KCI       2.6 mM 
 KH2PO4      1.2 mM 
 MgSO4 x 7H2O     1.2 mM 
 HEPES      22 mM  
 
3.4 Protein detection 
 
3.4.1 Preparation of Samples  
 
 After treatment, cells were lysed in pre-heated 2x SDS lysis buffer. Then cell 
lysate was scraped and collected in a 1.5 ml Eppendorf tube. Samples were 
denatured for 10 minutes at 65 °C and used immediately or stored at –20 °C. 
 
2x SDS loading sample buffer (100 ml) 
 
 Tris/HCI (pH 6.8)    250 mM 
 Glycerol (vol/vol)    20% 
 SDS (wt/vol)     4% 
 β-mercaptoethanol (vol/vol)  1% 
 bromphenol blue (wt/vol)   0.001%  
 DTT      10 mM 
 
3.4.2 Preparation of SDS-polyacrylamide gel electrophoresis (SDS PAGE) 
 
 The SDS gel apparatus was assembled after cleaning the glass plates with 
water and ethanol. The resolving gel solution of (12.5%) was prepared according to 
the volume of solutions as given below. TEMED and ammonium persulfate (APS) 
were added when the gel was ready to pour. The resolving gel was poured (app. 8.5 
cm height), and overlayed a thin layer of water. After polymerization of the resolving 
gel, the stacking gel solution was poured and a comb was inserted to create the 
30 
 
wells. After polymerization of the stacking gel, the comb was removed and the gel 
was ready for electrophoresis.  
 
Solutions Resolving gel Stacking gel 
 12.5% 6% 
Distilled water 9.8 ml 17.5 ml 
Acrylamide 40% (wt/vol) 12.7 ml 3.8 ml 
Bisacrylamide 2% (wt/vol) 7.0 ml 2.0 ml 
Separating gel buffer Tris/HCl; 
120 mM (pH 8.8)  
9.5 ml ------ 
Stacking gel buffer Tris/HCl; 
120 mM (pH 6.8)  
------ 6.0 ml 
SDS 10% (wt/vol) 400 μl 250 μl 
TEMED 30 μl 20 μl 
APS 10% (wt/vol) 400 μl 250 μl 
 
3.4.3 Electrophoresis 
 
 1x running gel buffer was prepared and added to the electrophoresis chamber. 
The comb was removed and wells were washed. Protein samples were denatured at 
65 °C for 10 minutes. The denatured samples were loaded into the wells with a 
Hamilton syringe. Finally, the gel was run at 45 voltages over night to separate the 
protein bands.  
 
1x running buffer: 
 
 Tris      250 mM 
 Glycine     2.0 M  
 SDS (wt/vol)     10 %  
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3.4.4 Electroblotting (Western blot) 
 
 Proteins were transferred onto a nitrocellulose membrane by using semi dry 
blotting method. Whatman 3M filter papers were cut to size of the gels, wetted in 1x 
blotting buffer, and three of these were placed onto the anode of the semi dry blotting 
chamber. The prewetted nitrocellulose membrane was put on the filter papers and 
the gel placed onto the nitrocellulose membrane. After that three more prewetted 
filter papers placed onto the gel. The membrane and the gel were gently pressed to 
remove air bubbles between the layers. The graphite cathode was put on top of the 
stack. The blot was connected to the power supply and it was run at 0.9 mA/cm2 of 
the gel area for 1-2 hours. 
 
1x blotting buffer 
 
 Tris/HCl      25 mM 
 Glycine      150 mM 
Methanol (vol/vol)     10%  
 
3.4.5 Ponceau staining  
 
 After blotting, the nitrocellulose membrane was washed with water for 4-5 
minutes. To estimate the efficiency of protein transfer, the membrane was stained 
with ponceau S for 5 minutes on a shaker. This stain is reversible and produces pink 
bands of proteins to show whether the transfer was successful. The membrane was 
destained by washing with TBST (1x TBS + 0.1% (vol/vol) Tween 20) on a shaker for 
10 minutes. 
 
3.4.6 Immunodetection of proteins 
 
 After de-staining by washing with TBST, the membrane was incubated in 
blocking solution (3% (wt/vol) BSA in 1x TBST) for 1 hour at room temperature.  
 After blocking, the membrane was incubated with primary antibody (1:1000 in 
3% (wt/vol) BSA) overnight at 4 °C under constant shaking. Afterwards, the 
membrane was washed with TBST 3-4 times for 10-15 minutes at room temperature. 
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Then the membrane was incubated with secondary antibody (1:1000 in 3% (wt/vol) 
BSA) for 1 hour at room temperature. Subsequently the membrane was washed with 
TBST 3-4 times for 10-15 minutes. 
 Then the membrane was incubated with enhanced chemiluminescence (ECL) 
solution for 1 minute. The luminescence was detected and recorded with Bio-Rad 
Quantity One gel documentation system and PeqLab Fusion system. 
 
Solutions 
 
10x Tris-buffered saline (TBS) 
 Tris/HCl (pH 7.4)     100 mM 
 NaCl       1.6 M 
 
TBS Tween (TBST) 
 
1x TBS 
Tween 20 (vol/vol) 0.1%  
 
Primary Antibodies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibodies Dilution factor 
Anti-CPI-17; rabbit IgG 1:1000 
Anti-Phospho-CPI-17; rabbit IgG 1:1000 
Anti-MLC; Clone MY-21; mouse IgM 1:1000 
Anti-Phospho-MLC; rabbit IgG 1:1000 
Anti-MYPT1; rabbit gG 1:1000 
Anti-Phospho-MYPT850; rabbit IgG 1:1000 
Anti-Actin; Clone AC-40; mouse.IgG 1:1000 
Anti-Vinculin; Clone hVIN-1; mouse IgG 1:1000 
Anti-α-Tubulin;  mouse IgG 1:1000 
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Secondary antibodies, horseradish peroxidase (HRP)-labeled 
 
Antibodies Dilution factor 
Anti-rabbit; IgG; HRP-Conjugate; from donkey 1:1000 
Anti-mouse; IgG; HRP-Conjugate; from sheep 1:1000 
Anti-mouse; IgM; HRP-Conjugate; from goat 1:1000 
 
All antibodies were diluted in 3% (wt/vol) BSA in 1x TBST. 
 
3.5 Stripping and reprobing  
 
Stripping solution: (50 ml)  
1M Tris/HCl (pH 6.8) 
10% SDS (wt/vol)  
Millipore H2O 
 
 To reprobe the membranes with antibodies against other proteins of the same 
or equal size, bound antibodies were removed by incubating the membranes with 
prewarmed stripping buffer for 2-5 minutes at room temperature under constant 
shaking. Subsequently membranes were washed extensively with TBST buffer, 
blocked and reprobed with appropriate antibodies. 
 
3.6 Measurement of endothelial monolayer permeability 
 
 The endothelial permeability was measured according to Noll et al. (1999), 
using a two compartment (luminal and abluminal compartments) system model. The 
luminal and abluminal compartments were separated by a polycarbonate filter 
membrane. The medium in the abluminal compartment was continuously stirred and 
the entire system was placed in a water bath at 37 °C. The luminal compartment 
contained 2.5 ml while the abluminal compartment contained 6.5 ml of normoxic 
medium. There was no difference in hydrostatic pressure between the luminal and 
abluminal compartment. The diffusion of trypan blue-labeled albumin from the luminal 
to the abluminal compartment was measured continuously with a spectrophotometer 
(Specord 10, Zeiss Jena, Germany). In a set of experiments, the medium of the 
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luminal and abluminal compartment contained EC-Oxyrase (1 U/ml) at pH 6.4 for 45 
minutes, to expose cell to simulated ischemia. Afterwards, the filters were mounted 
into the permeability apparatus and albumin flux was determined under 
reoxygenation conditions. 
 
 The albumin flux (F) was measured in mol/ (sec x cm2) through endothelial 
monolayer. Area (S) was calculated as the increase in albumin concentration (d[A]2) 
during the time interval (dt) in the abluminal compartment with the volume (V) as 
follows: 
     d[A]2 / dt x V 
    F =     ------------------ 
               S 
     
The combined permeability coefficient (P [cm/sec]) of both endothelial cell monolayer 
and filter membrane was calculated as: 
 
 
      F 
    P =       ---------------- 
        ([A]1 – [A]2) 
 
Where [A]1 and [A]2 are the albumin concentrations in the luminal and abluminal 
compartments, respectively. 
 
3.7 Downregulation of CPI-17 
 
 Short interfering RNA (siRNA) was used to silence endogenous CPI-17 in 
cultured HUVEC. Cells were treated with CPI-17 specific siRNA duplex. Duplex of 
sense 5'-ACCUGUCGAGGACUUCAUCdTdT-3' and antisense 3'-
GAUGAAGUCCUCGACAGGUdTdT-5' siRNA was used for downregulation of CPI-
17 as described before (Kolosova et al., 2004). Non-specific siRNA duplex was used 
as control treatment. Endothelial cells were seeded on 35-mm cell culture dishes (for 
Western blotting), on Transwell filters (for permeability experiments) and on glass-
cover slips (for immunostaining). Confluent cells were transfected with 200 nM CPI-
17 specific siRNA or non-specific siRNA using FuGENE 6 transfection reagent 
according to manufacturer‘s instructions. Experiments were performed after 48 hours 
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of transfection and downregulation of CPI-17 was determined by Western blot 
analysis. 
 
Transfection procedure: 
 
 Transfection was carried out with 200 nM of siRNA. A calculation for one 
sample is given below. The total volume was 1200 μl. Two solutions were prepared 
in two different tubes. 
Solution A. 50 μM siRNA (4.8 μl) was mixed with 95.2 μl Opti-MEM I medium. 
Solution B. FuGENE (3 μl) was mixed with 97 μl Opti-MEM I medium. 
 
 Solution A and solution B were prepared and vortexed for 10 seconds and 
incubated at room temperature for 10 minutes. Afterwards, the solution A was mixed 
with solution B, mixed properly by vortexing, and incubated for 40 minutes at room 
temperature. During this period, cell culture medium was removed, and 1 ml Opti-
MEM I medium was added. After 40 minutes, 200 μl transfection medium was added 
and cells were incubated under standard conditions at 37 ºC, 5% CO2 for 5 hours. 
Afterwards the transfection medium was replaced with the cell culture medium and 
respective experiments were performed after 48 hours. 
 
3.8 Immunostaining  
 
 The cell monolayers were exposed to 45 minutes of ischemia followed by 15 
min of reperfusion. Then cells were fixed with 4% (wt/vol) paraformaldehyde (PFA) in 
PBS for 15 minutes at room temperature or with cold methanol for 15-20 minutes at -
20 °C. Fixed cells were incubated with 0.2% (vol/vol) Triton X-100/TBS to 
permeabilize for 10 minutes at room temperature followed by blocking with 5% 
(wt/vol) BSA/1xTBS/0.1% (vol/vol) Tween 20. After blocking, cells were incubated 
with primary antibodies at 4 °C for overnight. Primary antibodies (anti-VE-cadherin 
(C-19); goat IgG and anti-catenin-beta; mouse IgG) were diluted 1:200 in blocking 
solution. Actin was stained by phalloidin-TRITC. Next day, cells were washed with 1x 
TBS/0.1% (vol/vol) Tween 20 for 10-20 minutes. Then cells were incubated with 
desired secondary antibodies diluted in blocking solution at room temperature for 1 
hour. Secondary antibodies used: Anti-goat IgG; TRITC 1:500; and Anti-mouse IgG; 
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Alexa fluor 488 donkey 1:200 respectively. Afterwards, cells were washed with 1x 
TBS/0.1% (vol/vol) Tween 20 for 10-20 minutes. Cells were mounted with 90% 
(vol/vol) glycerol/PBS. The prepared slides were visualized under confocal 
microscope, Zeiss LSM 510. 
 
3.9 Statistical analysis 
 
 Data are given as means ± SEM of 3 experiments of independent cell 
preparations as given in the legends to figures. Data of macromolecule permeability 
were given as mean + SD. Comparison of means of several groups was performed 
by one-way analysis of variance (ANOVA) followed by Bonferroni's multiple 
comparison test. Statistical analysis was performed by GraphPAd Prism, version 5 
for Windows (GraphPad software Incorporation, San Diego, USA) Probability (P) 
values less than 0.05 were considered significant (P< 0.05). 
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4 Results 
 
4.1 Effect of ischemia-reperfusion on EC barrier function 
 
 To analyze the effect of reperfusion on endothelial barrier function flux of 
albumin across cultured PAEC monolayers was determined. Under normoxic 
conditions the permeability did not change during the whole period of incubation (Fig. 
4.1). Exposure to simulated ischemia (Po2 < 1 mmHg, pH 6.4) led to an increase of 
albumin permeability after 45 min (endischemic value). With the onset of 
reoxygenation permeability was further increased, reaching a maximum level after 15 
min, and then decreased during the ongoing 30 min of incubation.  
 
 
    
 
Figure 4.1 Effect of ischemia-reperfusion on albumin permeability of porcine aortic 
endothelial cells (PAEC). (N) Control cells were exposed to normoxia (Po2 = 100 
mmHg, pH 7.4). (I) Cells were exposed to simulated ischemia (Po2 < 1 mmHg, pH 
6.4) for 45 min. (Reperfusion) Following ischemia cells were reperfused by medium 
change (Po2 = 100 mmHg, pH 7.4) and permeability was determined at time 15, 30, 
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and 45 min, respectively. Data are presented as means ± SEM of 3 separate 
experiments of independent cell preparations. P < 0.05: *I vs. N, #Reperfusion vs. I. 
 
4.2 Effect of ischemia-reperfusion on actin cytoskeleton and adherens 
junction proteins  
 
 A major determinant of endothelial barrier function is the integrity of the actin-
based cytoskeleton and cell adhesion structures. It is well established that distortion 
of both structures lead to cell retraction, opening of intercellular gaps and capillary 
leakage (Kuhne et al., 1993; Sutton et al., 2003; Glyn and Ward, 2002; Shi et al., 
2009).  
 
To analyze the effect of ischemia-reperfusion on actin cytoskeleton and 
endothelial adhesion structures, PAEC were exposed to simulated ischemia followed 
by 15 min of reperfusion. As shown in fig. 4.2, actin fibers bundles are arranged as 
cortical band at the cell periphery in normoxic control cells. After 45 min of ischemia 
actin cytoskeleton becomes largely rearranged and stress fibers are formed 
traversing the cells. Disintegration of actin cytoskeleton and stress fiber formation is 
further enhanced after 15 min of reperfusion. Disintegration of the actin cytoskeleton 
coincides with VE-cadherin/ß-catenin-based adherense junctions during simulated 
ischemia and reperfusion, indicated by translocation of both proteins from cell 
borders, where both nicely decorate cell-cell contacts under normoxic conditions. 
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Figure 4.2 Effect of ischemia-reperfusion on localization of actin cytoskeleton and 
the adherens junction proteins ß-catenin and VE-cadherin in PAEC monolayers. 
(Normoxia) control cells were exposed to normoxic conditions (Po2 = 100 mmHg, pH 
7.4). (Ischemia) cultured monolayers were exposed to simulated ischemia (Po2 < 1 
mmHg: pH 6.4) for 45 min. (Reperfusion) Following ischemia cells were exposed to 
reperfusion by medium change (Po2 = 100 mmHg, pH 7.4) for 15 min. Arrowheads 
denote F-actin stress fibers, which traverse endothelial cells, or delocalization of ß-
catenin and VE-cadherin at endothelial cell borders. One representative image of at 
least three independent experiments is given. Bar = 20 m. 
 
4.3 Effect of ischemia-reperfusion on MLC phosphorylation  
 
 Activation of the endothelial contractile machinery is the second key 
determinant of barrier function. Since the endothelial contractile machinery is 
activated by phosphorylation of the regulatory MLC leading to barrier dysfunction in 
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macro-vascular and micro-vascular endothelium (Yuan et al., 1997), this parameter 
was analyzed during ischemia-reperfusion. To that end, PAEC were exposed to 
simulated ischemia for 45 min followed by reperfusion and MLC phosphorylation was 
determined at the end of ischemia and during the ongoing reperfusion. As shown in 
fig. 4.3, MLC phosphorylation was increased during ischemia and persisted at 
elevated levels during 45 min of reperfusion.  
 
  
 
Figure 4.3 Effect of ischemia-reperfusion on MLC phosphorylation of PAEC.   
(N) Control cells were exposed to normoxia (Po2 = 100 mmHg). (I) Cells were 
exposed to simulated ischemia (Po2 < 1 mmHg, pH 6.4) for 45 min. (Reperfusion) 
Following ischemia cells were reperfused by medium change (Po2 = 100 mmHg, pH 
7.4) and MLC phosphorylation was determined at time 15, 30, and 45 min, 
respectively. (A) Representative Western blot showing MLC phosphorylation 
(MLC~P) at Ser19 compared to MLC total. (B) Densitometric analysis of the Western 
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blots. MLC phosphorylation relative to MLC total was given as x-fold increase to 
normoxia. The ratio of normoxia was set to 1. Data are presented as means ± SEM 
of 3 separate experiments of independent cell preparations. P < 0.05: *I vs. N, 
#Reperfusion vs. N. 
 
4.4 Effect of MLCK inhibition on ischemia-reperfusion-induced MLC 
phosphorylation  
 
 It is well established that MLCK is one of the most important kinase which 
directly phosphorylate MLC at Ser19 and causes barrier dysfunction (Garcia et al., 
1995; Goeckeler and Wysolmerski, 1995; Yuan et al., 1997). Therefore, the role of 
this kinase upstream of MLC phosphorylation was assessed during ischemia-
reperfusion. PAEC were exposed to simulated ischemia for 45 min followed by 15 
min of reperfusion in the presence and absence of 10 µM ML-7, a specific inhibitor 
added at optimum concentration to completely inhibit MLCK. As shown in fig. 4.4, 
ML-7 reduces reperfusion-induced MLC phosphorylation, but not below the level of 
normoxic cells, indicating that MLCK is involved in MLC phosphorylation stimulated 
by ischemia-reperfusion. 
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Figure 4.4 Effect of MLCK inhibition on ischemia-reperfusion-induced MLC 
phosphorylation in PAEC. (N) Control cells were exposed to normoxia (Po2 = 100 
mmHg, pH 7.4). (I) Cells were exposed to simulated ischemia (Po2 < 1 mmHg, pH 
6.4) for 45 min. (Reperfusion) Following ischemia cells were reperfused by medium 
change (Po2 = 100 mmHg, pH 7.4) and MLC phosphorylation was determined after 
15 min in presence of 10 µM ML-7. (A) Representative Western blot showing MLC 
phosphorylation (MLC~P) at Ser19 compared to MLC total. (B) Densitometric 
analysis of the Western blots. MLC phosphorylation relative to MLC total was given 
as x-fold increase to normoxia. The ratio of normoxia was set to 1. Data are 
presented as means ± SEM of 3 separate experiments of independent cell 
preparations. P < 0.05: *I vs. N, #R vs. N, §R+ML-7 vs. R alone. 
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4.5 Effect of ischemia-reperfusion on MYPT1 phosphorylation  
 
 MLC phosphorylation is balanced by MLCK and MLCP, the latter of which is 
inhibited by phosphorylation of its regulatory subunit MYPT1 at Thr850. To analyze 
the activation state of MLCP, the phosphorylation of MYPT1 was determined after 45 
min of simulated ischemia and during 45 min of reperfusion in PAEC. As shown in fig. 
4.5, ischemia caused an increase in MYPT1 phosphorylation, which is reduced 
during reperfusion, but is maintained significant elevated compared to the normoxic 
level, indicating that MLCP is inhibited during ischemia-reperfusion. 
 
  
 
Figure 4.5 Effect of ischemia-reperfusion on MYPT1 phosphorylation in PAEC. (N) 
Control cells were exposed to normoxia (Po2 = 100 mmHg, pH 7.4). (I) Cells were 
exposed to simulated ischemia (Po2 < 1 mmHg, pH 6.4) for 45 min. (Reperfusion) 
Following ischemia cells were reperfused by medium change (Po2 = 100 mmHg, pH 
7.4) and MYPT1 phosphorylation was determined at time 15, 30, and 45 min, 
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respectively. (A) Representative Western blot showing MYPT1 phosphorylation at 
Thr850 relative to MYPT1 total (B) Densitometric analysis of Western blot. MYPT1 
phosphorylation relative to MYPT1 total was given as x-fold increase to normoxia. 
The ratio of normoxia was set to 1. Data are presented as means ± SEM of 3 
separate experiments of independent cell preparations. P < 0.05: * I vs. N, 
#Reperfusion vs. N. 
 
4.6 Effect of ischemia-reperfusion on CPI-17 phosphorylation 
 
 CPI-17 is a small regulatory protein of PP1 catalytic subunit of the MLCP. In its 
phosphorylated state, CPI-17 can bind to PP1 and inhibit the phosphatase activity. 
Formerly, CPI-17 has been identified in smooth muscle cells, but is also expressed in 
endothelial cells and represents another mechanism for inhibition of MLCP activity. 
Therefore, CPI-17 phosphorylation was analyzed in the present study to support the 
concept that MLCP is inhibited during ischemia-reperfusion. As shown in fig. 4.6, 
CPI-17 phosphorylation is below the detection level in normoxic PAEC. However, 
exposure of the cells to 45 min of simulated ischemia caused a significant increase in 
CPI-17 phosphorylation, which maintained on the elevated level during reperfusion, 
indicating that CPI-17 persisted in its inhibitory state during ischemia-reperfusion. 
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Figure 4.6 Effect of ischemia-reperfusion on CPI-17 phosphorylation at Thr38 in 
PAEC. (N) Control cells were exposed to normoxia (Po2 = 100 mmHg, pH 7.4). (I) 
Cells were exposed to simulated ischemia (Po2 < 1 mmHg, pH 6.4) for 45 min. 
(Reperfusion) Following ischemia cells were reperfused by medium change (Po2 = 
100 mmHg, pH 7.4) and CPI-17 phosphorylation was determined at time 15, 30, and 
45 min, respectively. (A) Representative Western blot showing CPI-17 
phosphorylation relative to CPI-17 total. (B) Densitometric analysis of the Western 
blots. CPI-17 phosphorylation relative to CPI-17 total was given. Data are presented 
as means ± SEM of 3 separate experiments of independent cell preparations. P < 
0.05: *I vs. N, #Reperfusion vs. N. 
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4.7 Effect of RhoA/ROCK and PKC on phosphorylation of MYPT1, CPI-17, 
and MLC during ischemia-reperfusion 
 
 The phosphorylation state of both regulatory subunits of the MLCP 
holoenzyme complex is controlled by RhoA/ROCK and PKC pathway, leading to 
inhibition of MLCP activity. Here, the question was tested whether MYPT1 and/or 
CPI-17 is phosphorylated by one or both kinase pathways during ischemia-
reperfusion. To that end, phosphorylation of MYPT1 at Thr850 and CPI-17 at Thr38 
was analyzed in PAEC after 45 min of ischemia and 15 min of reperfusion. In sets of 
experiments 8 µM bisindolylmaleimide (BIM), a pan-specific pharmacological inhibitor 
of PKC, or 20 µM Y-27632, a specific pharmacological ROCK inhibitor, was added at 
the onset of reperfusion. As shown in fig. 4.7A, inhibition of the PKC, as well as the 
RhoA/ROCK pathway, decreased MYPT1 phosphorylation below the normoxic 
values indicating that both pathways are involved, not only in ischemia-reperfusion-
induced MYPT1 phosphorylation, but also in the controls under basal normoxic 
conditions. 
 
 Compared to the effect on MYPT1 phosphorylation, inhibition of ROCK and 
PKC only blunts ischemia-reperfusion-induced CPI-17 phosphorylation (Fig. 4.7B), 
indicating that both kinases are only partially involved in the control of the CPI-17 
phosphorylation state. 
 
 In a final set of experiments it was tested whether the manoeuvre causing 
dephosphorylation of MYPT1 and CPI-17 affects the phosphorylation state of the 
regulatory subunit of myosin. As shown in fig. 4.7C, exposure of PAEC to BIM or Y-
27632 at the onset of reperfusion in order to block PKC or ROCK, decreased MLC 
phosphorylation below the normoxic value. The observation that MYPT1 and CPI-17 
dephosphorylation in response to inhibition of PKC or ROCK coincide with the 
reduction in MLC phosphorylation during ischemia-reperfusion supports the concept 
that inhibition of MLCP is involved in the activation of the contractile machinery under 
these conditions. 
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Figure 4.7 Effect of RhoA/ROCK and PKC on phosphorylation of MYPT1, CPI-17, 
and MLC during ischemia-reperfusion in PAEC. (N) Control cells were exposed to 
normoxia (Po2 = 100 mmHg, pH 7.4). (I) Cells were exposed to simulated ischemia 
(Po2 < 1 mmHg, pH 6.4) for 45 min. (R) Following ischemia cells were reperfused by 
medium change (Po2 = 100 mmHg, pH 7.4) for 15 min in presence of 8 µM BIM 
(R+BIM) or 20 µM Y-27632 (R+Y). (A) Effect of RhoA/ROCK and PKC on 
phosphorylation of MYPT1. (Top) Representative Western blot showing MYPT1 
phosphorylation at Thr850 relative to MYPT1 total. (Bottom) Densitometric analysis of 
MYPT1 phosphorylation. MYPT1 phosphorylation relative to MYPT1 total was given 
as x-fold increase to normoxia. The ratio of normoxia was set to one. Data are 
presented as means ± SEM of 3 separate experiments of independent cell 
preparations. P < 0.05: * I vs. N, #R vs. N, §R+ BIM or §R+Y vs. R alone. (B) Effect of 
MLC total
MLC~P
IN
1
0.5
0
1.5
2
R R+BIM R+Y
A
B
n.s
20 kDa
20 kDa
*
M
LC
 ~
P
/M
LC
 t
o
ta
l (
x
-f
o
ld
o
f N
)
#
 
 
49 
 
ROCK and PKC inhibition on CPI-17 phosphorylation. (Top) Representative Western 
blot showing CPI-17 phosphorylation at Thr38 relative to CPI-17 total. (Bottom) 
Densitometric analysis of CPI-17 phosphorylation. CPI-17 phosphorylation relative to 
CPI-17 total was given as. Data are presented as means ± SEM of 3 separate 
experiments of independent cell preparations. P < 0.05: * I vs. N, #R vs. N, §R+BIM or 
§R+Y vs. R alone. (C) Effect of ROCK and PKC inhibition MLC phosphorylation (Top) 
Representative Western blot showing MLC phosphorylation relative to MLC total. 
(Bottom) Densitometric analysis of MLC phosphorylation. MLC phosphorylation 
relative to MLC total was given as x-fold increase to normoxia. The ratio of normoxia 
was set to one. Data are presented as means ± SEM of 3 separate experiments of 
independent cell preparations. P < 0.05: *I or #R vs. N, §R+BIM or §R+Y vs. R alone, 
n.s.: not significantly different. 
 
4.8 Effect of PKC inhibition on ischemia-reperfusion-induced macromolecule 
permeability, F-actin cytoskeleton and adherence junctions 
 
 To prove the impact of PKC inhibition on ischemia-reperfusion induced barrier 
failure, PAEC were exposed to simulated ischemia for 45 min followed by 15 min of 
reperfusion. In a set of experiments 8 µM BIM was added to the cells. As shown in 
fig. 4.8A, inhibition of the PKC pathway significantly reduced reperfusion-induced 
albumin permeability.  
 
 In a second step, the role of PKC on reperfusion-induced distortion of actin 
cytoskeleton and adherens junction was analyzed. To that end, PAEC were exposed 
to 45 min of ischemia followed by 15 min of reperfusion as described in (4.2). In a set 
of experiments PAEC were reperfused in presence of 8 µM BIM (8 μM).  
 
 As shown in fig. 4.8B, BIM attenuated the ischemia-reperfusion-induced stress 
fiber formation, and restored the ribbon like distribution of VE-cadherin at cell-cell 
junctions during reperfusion. 
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Figure 4.8 (A) Effect of PKC inhibition on ischemia-reperfusion-induced 
macromolecule permeability in PAEC. (N) Control cells were exposed to normoxia 
(Po2 = 100 mmHg, pH 7.4). (I) Cells were exposed to simulated ischemia (Po2 < 1 
mmHg, pH 6.4) for 45 min. Following ischemia cells were reperfused by medium 
change (Po2 = 100 mmHg, pH 7.4) in absence (R) or presence of 8 µM BIM (R+BIM) 
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for 45 min. Data are presented as means ± SEM of 3 separate experiments of 
independent cell preparations.  P<0.05: *I vs. N, #R vs. N, §R+BIM vs. R alone. (B). 
Effect of PKC inhibition on distortion of actin cytoskeleton and VE-cadherin in PAEC 
monolayers. Control cells were exposed to normoxic conditions (N) and simulated 
ischemia (I) as in (A). Afterwards cells were reperfused as in (A) by medium change 
for 15 min with (R+BIM) and without (R) PKC inhibitor 8 µM BIM. Arrowheads denote 
F-actin stress fibers, which traverse endothelial cells, or delocalization of VE-cadherin 
at endothelial cell borders. One representative image of at least three independent 
experiments is given. Bar = 20 m. 
 
4.9 Effect of CPI-17 silencing on ischemia-reperfusion-induced MLC 
phosphorylation 
 
 As shown above, CPI-17 is strongly phosphorylated during ischemia and 
persists on a high level during reperfusion (Fig. 4.6 and 4.7B). This high level of CPI-
17 phosphorylation coincided with the elevated level of MLC phosphorylation (Fig. 
4.3). In contrast, MYPT1 has already declined to the normoxic value during 
reperfusion. Thus, the CPI-17, the endogenous inhibitor of PP1 catalytic subunit, 
appears to be an important regulator in MLC phosphorylation and contractile 
activation in endothelial cells. 
 
To further support this conclusion, HUVEC were treated with CPI-17 specific 
siRNA (200 nM) or negative siRNA for 48 h to reduce the endothelial content of CPI-
17. Afterwards the cells were exposed to 45 min of ischemia followed by 15 min of 
reperfusion. As shown in fig. 4.9, HUVEC, as PAEC, express CPI-17. Reduction of 
CPI-17 by gene silencing led to dephosphorylation of MLC under basal conditions 
and prevented MLC phosphorylation during ischemia as well as reperfusion.  
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Figure 4.9  Effect of CPI-17 silencing on MLC phosphorylation during ischemia-
reperfusion. HUVEC were treated with CPI-17 specific siRNA or negative (neg) 
siRNA for 48 h. (N) Control cells were exposed to normoxia (Po2 = 100 mmHg, pH 
7.4)). (I) Cells were exposed to simulated ischemia (Po2 < 1 mmHg, pH 6.4) for 45 
min. (R) Following ischemia cells were reperfused by medium change (Po2 = 100 
mmHg, pH 7.4) for 15 min. Representative Western blot shows MLC phosphorylation 
relative to CPI-17 total. Actin was used as loading control. 
 
4.10 CPI-17 silencing restores ischemia-reperfusion-induced distortion of 
actin cytoskeleton and adherens junctions 
 
 In a second step, the effect of CPI-17 silencing on ischemia-reperfusion-
induced disruption of cell adhesion molecules was analyzed. Therefore, HUVEC 
were treated with CPI-17 specific siRNA (200 nM) or neg siRNA for 48 h, which has 
been proven to effectively reduce cellular CPI-17 protein content (Fig. 4.9). 
Afterwards, cells were exposed to 45 min of ischemia followed by 15 min of 
reperfusion. 
 
 As shown in fig. 4.10, silencing of CPI-17 restores disruption of intercellular 
junction proteins. VE-cadherin reappeared at cell-cell junctions in CPI-17 siRNA 
transfected cells as compared to control siRNA during reperfusion. The effect of CPI-
17 silencing on reperfusion-induced distortion of actin cytoskeleton was also studied. 
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Formation of actin stress fibers is reduced in CPI-17 siRNA transfected cells, and 
actin bundles reside at the cell periphery even during ischemia-reperfusion.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 Effect of CPI-17 silencing on ischemia-reperfusion-induced distortion of 
actin cytoskeleton and VE-cadherin. HUVEC were treated with CPI-17 specific siRNA 
or negative (neg) siRNA for 48 h. (Normoxia) Control cells were exposed to normoxia 
(Po2 = 100 mmHg, pH 7.4). (Ischemia) Cells were exposed to simulated ischemia 
(Po2 < 1 mmHg, pH 6.4) for 45 min. (Reperfusion) Following ischemia cells were 
reperfused by medium change (Po2 = 100 mmHg, pH 7.4) for 15 min. Arrowheads 
show the dissolution of VE-cadherin and actin stress fiber formation in non-
transfected cells. Bar = 20 m. 
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4.11 CPI-17 silencing reduces reperfusion-induced albumin permeability  
 
 In a final step it was tested whether silencing of CPI-17 by siRNA affects 
endothelial barrier function during ischemia-reperfusion. To accomplish that, HUVEC 
were treated as described above to reduce the cellular content of CPI-17. Afterwards 
cells were exposed to 45 min of ischemia followed by 15 min of reperfusion. As 
shown in fig. 4.11, reduction of CPI-17 did not affect basal macromolecule 
permeability under normoxic conditions. However, macromolecule permeability of 
CPI-17 siRNA treated cells was significantly reduced when exposed to ischemia or 
reperfusion, indicating that CPI-17 plays an important role in endothelial barrier 
stabilization. 
 
 However, as can be depicted from fig. 4.11, albumin permeability is not 
completely reduced to the normoxic value in CPI-17 siRNA treated cells, when cells 
were exposed to reperfusion. Therefore, it was tested whether MLCK may also be 
involved in this situation. To that end, cells were exposed to ischemia for 45 min 
followed by reperfusion with 10 µM ML-7, to block MLCK activation during 
reperfusion. As shown in fig. 4.11, ML-7 reduces reperfusion-induced albumin 
permeability in siRNA transfected cells, indicating that MLCK is involved in 
reperfusion-induced hyperpermeability. The Ischemia-reperfusion-induced increase 
in permeability was completely resored, when MLCK was inhibited in CPI-17 siRNA 
silenced cells with the onset of reperfusion, supporting the concept that both, MLCK 
and MLCP, are involved in ischemia-reperfusion-induced hyperpermeability.  
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Figure 4.11 Effect of CPI-17 silencing and MLCK inhibition on ischemia-reperfusion-
induced hyperpermeability. HUVEC were treated with CPI-17 specific siRNA (dashed 
bars) or negative siRNA (open bars) for 48 h. (N) Control cells were exposed to 
normoxia (Po2 = 100 mmHg, pH 7.4). (I) Cells were exposed to simulated ischemia 
(Po2 < 1 mmHg, pH 6.4) for 45 min. (R) Following ischemia cells were reperfused by 
medium change (Po2 = 100 mmHg, pH 7.4) for 15 min. In a set of experiments, the 
cells were exposed to 10 µM ML-7, a specific inhibitor of MLCK, at the onset of 
reperfusion. *P < 0.05, n.s.: not significantly different.  
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5 DISCUSSION 
 
 Capillary leakage is the first indication of a disturbed endothelial barrier 
function during reperfusion of ischemic tissue. In the heart, as well as in other organs, 
failure of endothelial barrier causes extravasation of solutes, macromolecules and 
blood cells leading to edema formation, which jeopardize functional and structural 
recovery of the organ during reperfusion (Garcia et al., 2012). 
 
 There is a lot of indirect evidence from in vivo studies showing that capillary 
endothelial cells are stimulated to contract in the ischemia-reperfusion myocardium 
(Glyn and Ward, 2000). Likewise, exposure of endothelial monolayers to simulated 
ischemia induced an instant increase in cytosolic Ca2+ concentration, which coincided 
with an increase in interendothelial gap formation. During the following reperfusion 
the cytosolic Ca2+ concentration and gap formation was further enhanced, indicating 
that contractile activation and disturbance of cell adhesion structures are involved in 
endothelial barrier failure (Ladilov et al., 2000; Gündüz et al., 2006). Maneuver which 
blocks the Ca2+ increase also prevented the increase in gap formation in that model, 
demonstrating that the hyperpermeability induced by ischemia-reperfusion is 
triggered by cytosolic Ca2+ concentration. In a further study Schäfer et al. (2003) 
showed that the reperfusion-induced increase in gap formation can be blocked by 
inhibitors of the MLCK. This led to the concept that endothelial barrier failure induced 
during ischemia-reperfusion is, at least in part, caused by Ca2+-dependent activation 
of the contractile machinery. Although one of the most frequent and severe vascular 
complication, the mechanism of ischemia-reperfusion is not fully understood. 
Strategies for therapeutic intervention targeting the endothelium are not available 
today. 
 
The present study analyzed molecular mechanism involved in the endothelial 
barrier failure. Special focus was laid on the endothelial contractile machinery and 
cell-cell adhesion structures. Endothelial monolayers from porcine aortas and human 
umbilical veins, exposed to 45 min of simulated ischemic followed by 45 min of 
reperfusion, was chosen as a basis for the experimental paradigm. 
 
The major findings of the present study are:  
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(1) Exposure of PAEC to simulated ischemia induced an increase in macromolecule 
permeability which was further enhanced when the cells were reoxygenated. 
(2) The increase in permeability coincided with disturbance of the F-actin 
cytoskeleton and cell adhesion structures. 
(3) During ischemia-reperfusion phosphorylation of MLC, MYPT1 and CPI-17 was 
increased. This increase in phosphorylation was reduced, when EC were 
reperfused in presence of a panspecific inhibitor of PKC or ROCK. 
(4) Inhibition of PKC with the onset of reperfusion also reduced the reperfusion-
induced increase in macromolecule permeability. 
(5) CPI-17 silencing in HUVEC abolished reperfusion-induced MLC phosphorylation 
and restored reperfusion-induced distortion of the F-actin cytoskeleton and cell 
adherens junctions. It abolished the ischemia-induced increase in macromolecule 
permeability and reduced the increase in permeability induced by reperfusion. A 
complete reduction of the reperfusion-induced increase in permeability was 
observed when CPI-17 silenced cells were reperfused in the presence of an 
inhibitor of MLCK. 
 
5.1  Ischemia-Reperfusion induces rearrangement of actin cytoskeleton and 
distortion of adherens junctions 
 
 The actin cytoskeleton provides the mechanical strength to the cell and 
interacts with myosin filaments to provide the force of contraction. In the present 
study it was shown that the increase in macromolecule permeability of the endothelial 
monolayers coincided with disturbance of the F-actin cytoskeleton and cell adhesion 
structures, when the cells were exposed to ischemia and reperfusion. These findings 
show that the experimental procedure used in the present study is in accordance with 
the established concept of endothelial barrier function and integrity of the 
cytoskeleton (Mehta and Malik, 2006).  
 
 In the present study ischemia-reperfusion induced extensive rearrangement of 
the actin cytoskeleton. Changes in actin cytoskeleton had already started during 
ischemia and led to stress fiber formation which traversed the cells. During 
reperfusion distortion of the F-actin cytoskeleton proceeded. Peripheral actin bands 
were progressively fading while stress fiber formation was enhanced. Collectively, the 
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data suggests that the increase in permeability during ischemia, and the further rise 
in response to reperfusion are causally linked with the progressive alterations in actin 
cytoskeleton and disturbance of cell adhesion structures. 
 The data of the present study are in accordance to previous work from 
Partridge (1995). She has reported that hypoxia-reoxygenation induces 
rearrangement of the actin cytoskeleton, opening of intercellular gaps and an 
increase in endothelial monolayer permeability. The essential role of F-actin fibers in 
maintaining cell integrity has also been shown in epithelial cells during ischemia 
(Molitoris, 1991; Schwartz et al., 1999), indicating that this causal link between 
cytoskeleton and barrier function is not only confined to endothelial, but also on other 
epithelial cells. Kuhne et al. (1993) and Watanabe et al. (1991) have shown that even 
under normoxic conditions, energy depletion alone causes disintegration of actin 
bundles at the cell periphery and endothelial cell retraction, which coincides withan 
increase in macromolecule permeability. Disruption of microfilaments and 
depolymerization of microtubules has also been observed under ATP depletion 
conditions by other laboratories (Hinshaw et al., 1989), indicating that the 
disintegration of actin cytoskeleton and cell adhesion structures result, at least in 
part, from the loss of energy during ischemia, wherease, reorganization of the cell 
cytoskeleton starts again, when ATP synthesis starts again with the supply of oxygen 
at the onset of reperfusion. 
 
 In addition to the integrity of the F-actin cytoskeleton, maintenance of 
adherens junctions is important for the regulation of endothelial barrier function 
(Wallez and Huber, 2008; Bazzoni and Dejana, 2004). Adherens junctions are 
formed by interactions of VE-cadherin and β-catenin, the latter of which links VE-
cadherin to the actin cytoskeleton. Thus, paracellular permeability is increased when 
VE–cadherin and ß-catenin at cell-cell junctions disrupt (Rabiet et al., 1996; Corada 
et al., 1999; Weis et al., 2004; Monaghan and Burridge, 2009).  
 
In line with this concept, the data of the present study shows that endothelial 
monolayers exposed to ischemia-reperfusion undergo distortion of VE-cadherin and 
β-catenin at the cell periphery. Delocalisation of both proteins from cell borders has 
already started during ischemia and proceeded during reperfusion. 
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Taken together, ischemia and reperfusion cause barrier failure due to 
combined disturbance of cytoskeletal and cell adhesion structures. The process of 
endothelial malfunction starts during ischemia and is further enhanced when 
reperfusion sets on. Furthermore, the study has revealed that the experimental model 
of cultured cells used, shares fundamental characteristics regarding physiological 
barrier function of the intact coronary system in vivo. Therefore, it is an appropriate 
model to analyze the underlying molecular mechanisms of barrier failure.  
 
5.2 Ischemia-Reperfusion induces MLCK activation and MLCP inhibition  
 
 It is well established that the contractile activity of endothelial cells is controlled 
by phosphorylation of MLC, which in turn is regulated by at least two enzymes: an 
endothelial specific Ca2+/calmodulin-dependent 210 kDa MLCK (Lazar and Garcia., 
1999) and a MLCP (Knapp et al., 1999; Verin et al., 2000; Härtel et al., 2007) which 
is similar to the one expressed in smooth muscle cells. MLCK is an important kinase 
which directly phosphorylates MLC at Ser19 and regulates endothelial barrier 
function (Wysolmerski and Lagunoff, 1991). As already mentioned in the introduction, 
the endothelial MLCP is a holoenzyme complex formed by the PP1 catalytic subunit 
and the regulatory subunit MYPT1, which targets PP1 to myosin. When MYPT1 
becomes phosphorylated, MLCP is inhibited and the phosphatase complex 
disassembles (Härtel et al., 2007).  
 
 The data of the present study show that ischemia-reperfusion induces 
phosphorylation of both MLC and MYPT1. Application of the MLCK inhibitor ML-7 at 
optimum concentration, which completely blocks MLCK activity, reduced MLC 
phosphorylation only back to the normoxic level. These data are consistent with the 
assumption that reperfusion-induced activation of the contractile machinery depends 
on activation of MLCK and inhibition of MLCP. Likewise, addition of ML-7 at the onset 
of reperfusion caused only a partial reduction of reperfusion-induced 
hyperpermeability, supporting the concept that other signaling mechanism, in addition 
to MLCK, are involved in the control of contractile activation and barrier failure.  
 
 In accordance with the data of the present study, several reports in literature 
demonstrate that inhibition of MLCK by ML-7 reduce hypoxia-induced MLC 
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phosphorylation and barrier failure in cultured endothelial monolayers.  Schäfer et al. 
(2003) showed in monolayers of microvascular coronary endothelial cells from rat 
that ML-7 or Wortmannin, two chemical different inhibitors of MLCK, partially block 
reoxygenation-induced hyperpermeability. Kuhlmann et al. (2007) oberved in 
monolayers of microvascular endothelial cells from bovine brain that hypoxia induces 
phosphorylation of MLC, which coincided with loss of barrier function. In that model, 
application of ML-7 reduced MLC phosphorylation below the normoxic level and 
completely restored barrier integrity, indicating that mechanism counteracting MLC 
dephosphorylation, like MLCP, may be less active in this cell preparation. 
 
5.3 Reperfusion-induced MLCP inhibition mediated by RhoA activation 
 
 As mentioned above, the activity of the MLCP holoenzyme complex is 
regulated by phosphorylation of MYPT1. One of the most important intracellular 
trigger of MYPT1 phosphorylation is the RhoA/ROCK pathway (Kimura et al., 1996). 
In smooth muscle cells, as well as in many non-muscle cells, ROCK-dependent 
phosphorylation of MYPT1 led to inhibition of MLCP, increase in MLC 
phosphorylation, and activation of the actomyosin-based contractile apparatus (Feng 
et al., 1999; Hartshorne, 1987; Kimura et al., 1996). Y-27632, a specific 
pharmacological inhibitor of ROCK, has been shown to reduce phosphorylation of 
MYPT1 as well as MLC, and causes vasodilation (Shimokawa, 2002). In endothelial 
cells, two independent groups (Essler et al., 1998; van Nieuw Amerongen et al., 
1998) demonstrated that inactivation of the RhoA/ROCK pathway also led to 
inactivation of MLCP, increase in MLC phosphorylation, and an opening of 
intercellular gaps by activation of the endothelial contractile apparatus.  
 
In line with those findings, the data of the present study show that inhibition of 
ROCK by Y-27632 reduced ischemia-reperfusion induce increase in MLC and 
MYPT1 phosphorylation beyond the normoxic value. It also halved phosphorylation 
of CPI-17 compared to its endischemic value, indicating that the RhoA/ROCK 
pathway is activated under these conditions and may inhibit MLCP. This concept is 
consistent with previous studies showing that hypoxia-induced activation of ROCK 
contributes to the inhibition of MLCP in endothelial cells (Takemoto et al., 2002) as 
well as in smooth muscle cells (Wang et al., 2003). The mechanism, however, which 
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activates RhoA/ROCK during ischemia-reperfusion is only poorly understood. One 
possible trigger could be the increase in cytosolic Ca2+ concentration during 
ischemia-reperfusion .  
   
5.4 Ischemia-reperfusion-induced MLCP inhibition is mediated by PKC and 
ROCK activation 
 
PKC isoforms and ROCK are well established modulators of the endothelial 
barrier function by targeting the contractile apparatus, cytoskeleton and cell adhesion 
structures at specific sides. Lynch et al. (1990) were among the first who 
systematically analyzed the effect of direct activation or inhibition of PKC on 
macromolecule permeability in cultured endothelial monolayers. Hempel et al. (1999) 
reported that the antagonist nifedipine prevents the ischemia-induced increase in 
permeability via PKC inhibition in cultured porcine endothelial cells, indicating that 
endothelial barrier failure can be triggered by Ca2+ via activation of PKC activation.  
 
 There is accumulating evidence that PKC and RhoA/ROCK signaling 
pathways are closely linked with each other. Hippenstiel et al. (1998) reported that 
inhibition of RhoA by Clostridium difficile toxin B prevented translocation and 
activation of PKC to plasma membrane in lipopolysaccharide as well as phorbol 
ester-stimulated HUVEC. The author concluded that RhoA is necessary for the 
activation and translocation of PKC to the endothelial plasma membrane. Patil et al. 
(2004) as well as Pang and Bitar (2005) could show that the interaction of RhoA and 
PKC-α is due to direct binding of RhoA to PKC. The resulting complex is translocated 
to the plasma membrane mediated by HSP27 in acetylcholine stimulated smooth 
muscle cells. Recently, He et al. (2012) have shown that inhibition of either PKC or 
Rho/ROCK causes similar reduction in transendothelial resistence of cultured 
monolayers, indicating that even basal endothelial barrier function is controlled by 
both pathways. Collectively, these data have led to the assumption that both 
signaling pathways may also be involved in ischemia-reperfusion-induced barrier 
failure. 
 
 In line with this, inhibition of endothelial PKC by a panspecific inhibitor BIM 
reduced ischemia-reperfusion induced increase in phosphorylation of MLC and 
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MYPT1 beyond normoxic values and halved the phosphorylation of CPI-17. The most 
prominent effect of PKC inhibition is observed on MYPT1 phosphorylation, which is 
similar to the one induced by ROCK inhibition under the same conditions, indicating 
that during ischemia-reperfusion PKC and RhoA/ROCK inhibit MLCP by targeting 
MYPT1. Inhibition of PKC or ROCK had only moderate effects on CPI-17 
phosphorylation indicate that there are other kinases involved. In accordance with 
this assumption, both inhibitors only halved the MLC phosphorylation level induced 
by ischemia-reperfusion.  
 
In addition to the effect on the contractile machinery, PKC may also target 
cytoskeletal proteins and cell adhesion structures leading to hyperpermeability. In the 
present study VE-cadherin and ß-catenin were analyzed because they are central 
proteins of endothelial junctions which are highly regulated by intracellular signaling 
mechanisms and important for endothelial barrier function (Rabiet et al., 1996; 
Gotsch et al., 1997; Hordijk et al., 1999; Corada et al., 2001; Waschke et al., 2004). 
The stability of the VE-cadherin-ß-catenin adhesion structures may by indirectly or 
directly influenced by PKC. Activation of the contractile machinery by PKC may affect 
VE-cadherin-mediated cell adhesion via ß-catenin, which links the actin cytoskeleton 
to cell adhesion protein complexes (Lampugnani et al., 1995; Dejana, 2004). On the 
other hand, PKC phosphorylation of strategic proteins of adhesion structures may 
weaken the VE-cadherin binding to the structures, leading to disassembly of 
adherens junctions and loss of barrier function (Vandenbroucke St Amant et al., 
2012).  
 
 In the present study it was shown that ischemia-reperfusion induced actin 
stress fiber formation, disruption of VE-cadherin and β-catenin at cell-cell junctions. 
Inhibition of PKC prevented the distortion of actin cytoskeleton and cell-cell junctions. 
Accordingly, inhibition of PKC reduced the reperfusion-induced permeability increase 
toward endischemic levels. This indicates that activation of PKC is responsible, at 
least in part, for the rearrangement of the actin cytoskeleton, disruption of adherens 
proteins and finally barrier malfunction. However, it does not fully account for 
ischemia-reperfusion hyperpermeability. In so far both, PKC and RhoA/ROCK are 
only partially involved in the deleterious mechanism.  
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To test new options for a therapeutic intervention against barrier failure, it was 
intriguing to identify a signaling element on which PKC and RhoA/ROCK converge. 
This led to the idea to test signaling mechanisms down-stream of both kinases. 
 
5.5 CPI-17 silencing reduces reperfusion-induced hyperpermeability 
 
CPI-17 is phosphorylated by several kinases including PKC, Rho kinase, 
zipper-interacting protein kinase, and integrin-linked kinase in smooth muscle cells 
(Hirano, 2007; Koyama et al., 2000). Phosphorylation of CPI-17 at Thr38 by PKC 
increases its inhibitory potency and activity towards MLCP (Eto et al., 1997; Kitazawa 
et al., 2000), which in turn controls the MLC phosphorylation level. Kitazawa et al. 
(2000) also reported that pharmacological inhibitors of PKC and ROCK-reduced CPI-
17 phosphorylation and smooth muscle contraction. 
 
 CPI-17 is also found in endothelial cells. Kolosova et al. (2004) described for 
the first time the expression of CPI-17 on mRNA level in lung microvascular and 
microvascular endothelial cells as well as in HUVEC. Because of its low protein 
expression, the authors overexpressed CPI-17 in pulmonary artery endothelial cells 
to analyze the possible role in endothelial cells. They found that expression of CPI-17 
enhances formation of stress fibers, focal adhesions and MLC phosphorylation if cells 
are stimulated by direct activators of PKC or by inflammatory mediators like histamin. 
Srinivas et al. (2006) showed expression of CPI-17 on protein level in corneal 
endothelial cells. Stimulation of histamine and thrombin led to an increase in CPI-17 
phosphorylation in these cells. Most recently, Aslam et al. (2010) demonstrated that 
CPI-17 is also expressed in HUVEC. In this model thrombin enhanced CPI-17 
phosphorylation and recruitment of the activated inhibitor to PP1. Phosphorylation of 
CPI-17 and its recruitment to MLCP coincided with an inhibition of PP1 activity. In 
addition, in CPI-17-silenced HUVEC the thrombin-induced increase in permeability 
was reduced. 
 
In the present study, using the same experimental model, downregulation of 
CPI-17 caused a decrease in MLC phosphorylation under normoxic conditions, 
indicating that MLC dephosphorylation is enhanced. On the other side, the fact that 
CPI-17 is phosphorylated suggested that there is a kinase activity already active 
64 
 
under basal conditions in HUVEC. Reduction of the MCLP inhibitor in siRNA-
downregulated cells obviously leads to an enhanced dephosphorylation. Under 
ischemia this enhanced phosphatase activity prevented MLC phosphorylation nearly 
completely and blunted it during reoxygenation. Downregulation of CPI-17 also 
reduced formation of actin stress fiber, disturbance of cell adhesion structures 
induced by ischemia, and enhanced the reorganization of VE-cadherin at the cell 
periphery during reperfusion. CPI-17 downregulation also abolished the ischemia-
induced increase in macromolecule permeability and reduced the increase in 
permeability induced by reperfusion. A complete reduction of the reperfusion-induced 
increase in permeability was observed when CPI-17-silenced cells were reperfused 
in the presence of an inhibitor of MLCK.  
 
Collectively, these data demonstrate that CPI-17 stabilizes actin cytoskeleton, 
cell-cell adhesion and reduces the contractile activation of endothelial cells. 
Furthermore, in combination with an inhibitor of MLCK it protects endothelial barrier 
against imminent failure. This makes CPI-17 an interesting target of therapeutic 
intervention to stabilize endothelial barrier and to prevent edema formation induced 
by ischemia-reperfusion and beyond.  
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Figure 5.1: In endothelial cells, ischemia-reperfusion (I/R) leads to an activation of 
the Ca2+-dependent MLCK and inhibition of the MLCP. The activation of the MLCK is 
triggerd by the increase in cytosolic Ca2+ concentration (Gündüz et al., 2006). 
Inhibition of MLCP may be mediated by PKC and RhoA/ROCK signaling pathways 
targeting the endogenous CPI-17 and MYPT1.  
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7 SUMMARY 
 
 Failure of endothelial barrier leading to capillary leakage and edema formation 
during reperfusion represents major impediment for the recovery of an organ. The 
endothelial barrier function is maintained by equilibrium of competing contractile and 
adhesive forces, generated by the actomyosin cytoskeleton and adherens junction 
proteins, respectively. The activity of the endothelial contractile machinery is 
regulated by the phosphorylation state of the myosin light chain (MLC), the activity of 
which is regulated by activities of MLC-kinase (MLCK) and MLC-phosphatase 
(MLCP). In the present study, the molecular mechanism of ischemia-reperfusion-
induced activation of the contractile machinery was analyzed, focusing on the 
involvement of protein kinase C (PKC) and Rho-associated kinase (ROCK)-mediated 
inhibition of MLCP. Furthermore, rearrangement of the actin cytoskeleton, loss of VE-
cadherin, and β-catenin from cell-cell adhesions were analyzed during ischemia-
reperfusion. Exposure of endothelial cells to severe ischemia (Po2 < 1 mmHg, pH 
6.4) for 45 min, followed by 45 min of reperfusion, caused an increase in 
macromolecule permeability and phosphorylation of MLC, myosin-targeting subunit of 
MLCP (MYPT1), and C-kinase potentiated protein phosphatase-1 inhibitor (CPI-17). 
ML-7 (10 µM), a pharmacological inhibitor of MLCK, partially reduced ischemia-
reperfusion-induced MLC phosphorylation and hyperpermeability. But also PKC 
inhibitor bisindolylmaleimide (8 µM) and Rho kinase inhibitor Y-27632 (20 µM) 
reduced ischemia-reperfusion-induced barrier dysfunction and phosphorylation of 
MLC, MYPT1, and CPI-17. Downregulation of CPI-17 by siRNA significantly 
abolished the ischemia-reperfusion-induced increase in permeability and led to actin 
cytoskeleton rearrangement and restoration of VE-cadherin at cell-cell adhesions. 
The data of the present study show for the first time that under ischemia-reperfusion 
CPI-17 is activated, it stimulates the contractile machinery and induces distortion of 
adherens junction proteins. These effects are prevented by downregulation of CPI-
17. The development of therapeutic strategies targeting CPI-17 provides a new 
option to protect against ischemia-reperfusion-induced barrier failure. 
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8 ZUSAMMENFASSUNG 
 
 Das Versagen der endothelialen Schranke führt zur kapillären Leckage und 
Ödembildung und ist ein Haupthindernis bei der Wiedererholung der Organfunktion 
im Verlauf der Reperfusion. Die endotheliale Barrierenfunktion wird durch das 
Gleichgewicht zweier konkurrierender Kräfte aufrechterhalten: den kontraktilen 
Kräften, vermittelt über das Actomyosin-Zytoskelett und den Haltekräften, vermittelt 
über Adherens Junctions. Die Aktivität des endothelialen kontraktilen Apparates wird 
über Phosphorylierung der Myosinleichtketten (MLC) reguliert, welche wiederum 
durch die Aktivitäten von MLC-Kinase (MLCK) und MLC-Phosphatase kontrolliert 
wird. In der vorliegenden Arbeit wurde der molekulare Mechanismus der Ischämie-
Reperfusion-induzierten Aktivierung des kontraktilen Apparates analysiert. Dabei lag 
der Schwerpunkt der Arbeit auf der Proteinkinase C (PKC)- und Rho-abhängigen 
Kinase (ROCK)-vermittelten Hemmung der MLKP. Darüber hinaus wurden 
Änderungen des Aktin-Zytoskeletts, die Translokation von VE-Cadherin und β-
Catenin aus den Zell-Zell-Adhäsionsstrukturen während Ischämie-Reperfusion 
untersucht. Eine Ischämie (Po2 < 1 mmHg, pH 6,4) für 45 min, gefolgt von einer 45-
minütigen Reperfusion, verursachte einen Anstieg der Makromolekülpermeabilität 
und Phosphorylierung der MLC, Myosin-bindender Untereinheit der MLCP (MYPT1) 
und dem C-kinase potentiated protein phosphatase-1 inhibitor (CPI-17). ML-7 (10 
µM), ein pharmakologischer Inhibitor der MLCK, reduzierte die Ischämie-
Reperfusion-induzierte MLC-Phosphorylierung und Hyperpermeabilität teilweise. Der 
PKC-Inhibitor Bisindolylmaleimid (8 uM) und Rho-Kinase-Inhibitor Y-27632 (20 µM) 
reduzierte die Ischämie-Reperfusion-induzierte Schrankenstörung und 
Phosphorylierung von MLC, MYPT1 und CPI-17. Herunterregulation von CPI-17 
durch siRNA verminderte die Ischämie-Reperfusion-induzierte Steigerung der 
Permeabilität und bewirkte die Reorganisation des Aktin-Zytoskeletts und von VE-
Cadherin an den Zell-Zell Kontakten. 
Die Daten der vorliegenden Studie zeigen zum ersten Mal, dass unter Bedingungen 
einer Ischämie-Reperfusion CPI-17 aktiviert wird, welches den kontraktilen Apparat 
stimuliert und zur Störung der Adherens junctions beiträgt. Diese Wirkung kann durch 
Herunterregulieren von CPI-17 verhindert werden. Die Entwicklung von 
therapeutischen Strategien, die auf CPI-17 abzielen, stellt eine neuartige Option dar, 
um vor dem Ischämie-Reperfusion-induzierten Schrankenversagen zu schützen. 
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